
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25120546</article-id><article-id pub-id-type="pmc">4114188</article-id><article-id pub-id-type="doi">10.3389/fimmu.2014.00360</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Hypothesis and Theory</subject></subj-group></subj-group></article-categories><title-group><article-title>Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bruttel</surname><given-names>Valentin S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/149623"/></contrib><contrib contrib-type="author"><name><surname>Wischhusen</surname><given-names>J&#x000f6;rg</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/31111"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Section for Experimental Tumor Immunology, Department of Obstetrics and Gynecology, School of Medicine, University of W&#x000fc;rzburg</institution>, <addr-line>W&#x000fc;rzburg</addr-line>, <country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Salem Chouaib, Institut Gustave Roussy, France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Bozena Kaminska, Nencki Institute of Experimental Biology, Poland; Benjamin Bonavida, University of California Los Angeles, USA</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: J&#x000f6;rg Wischhusen, Section for Experimental Tumor Immunology, Department of Obstetrics and Gynecology, School of Medicine, University of W&#x000fc;rzburg, Josef-Schneider-Strasse 4, W&#x000fc;rzburg 97080, Germany e-mail: <email>wischhusen_J@ukw.de</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Tumor Immunity, a section of the journal Frontiers in Immunology.</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>5</volume><elocation-id>360</elocation-id><history><date date-type="received"><day>03</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>13</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Bruttel and Wischhusen.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Cancer stem cell (CSC) biology and tumor immunology have shaped our understanding of tumorigenesis. However, we still do not fully understand why tumors can be contained but not eliminated by the immune system and whether rare CSCs are required for tumor propagation.</p><p>Long latency or recurrence periods have been described for most tumors. Conceptually, this requires a subset of malignant cells which is capable of initiating tumors, but is neither eliminated by immune cells nor able to grow straight into overt tumors. These criteria would be fulfilled by CSCs. Stem cells are pluripotent, immune-privileged, and long-living, but depend on specialized niches. Thus, latent tumors may be maintained by a niche-constrained reservoir of long-living CSCs that are exempt from immunosurveillance while niche-independent and more immunogenic daughter cells are constantly eliminated.</p><p>The small subpopulation of CSCs is often held responsible for tumor initiation, metastasis, and recurrence. Experimentally, this hypothesis was supported by the observation that only this subset can propagate tumors in non-obese diabetic/scid mice, which lack T and B cells. Yet, the concept was challenged when an unexpectedly large proportion of melanoma cells were found to be capable of seeding complex tumors in mice which further lack NK cells. Moreover, the link between stem cell-like properties and tumorigenicity was not sustained in these highly immunodeficient animals. In humans, however, tumor-propagating cells must also escape from immune-mediated destruction. The ability to persist and to initiate neoplastic growth in the presence of immunosurveillance &#x02013; which would be lost in a maximally immunodeficient animal model &#x02013; could hence be a decisive criterion for CSCs.</p><p>Consequently, integrating scientific insight from stem cell biology and tumor immunology to build a new concept of &#x0201c;CSC immunology&#x0201d; may help to reconcile the outlined contradictions and to improve our understanding of tumorigenesis.</p></abstract><kwd-group><kwd>tumor-propagating cells</kwd><kwd>tumor immunology</kwd><kwd>tumor immunosurveillance</kwd><kwd>tumor dormancy</kwd><kwd>latency</kwd><kwd>tumor immune escape</kwd><kwd>cancer stem cells</kwd><kwd>cancer stem cell immunology</kwd></kwd-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="170"/><page-count count="13"/><word-count count="11270"/></counts></article-meta></front><body><sec id="S1"><title>Introduction to Tumor Immunosurveillance</title><p>Cancer is caused by accumulating genetic alterations in a cell. These lead to activation or multiplication of proteins promoting cell growth and survival whereas proteins promoting cell cycle arrest or cell death are lost or inactivated. Every day no less than one million molecular lesions are thought to occur in the DNA of a single cell (<xref rid="B1" ref-type="bibr">1</xref>). While most of these are instantly repaired, the high number implies that very effective control mechanisms must exist to prevent the formation of tumors by mutant cells. This includes both cell-intrinsic mechanisms, such as DNA repair enzymes and tumor suppressor genes [comprehensively reviewed by Hanahan and Weinberg (<xref rid="B2" ref-type="bibr">2</xref>)], and the cell-extrinsic control function of the immune system, as first postulated by Paul Ehrlich more than a century ago and systematically introduced by Burnet in 1953 (<xref rid="B3" ref-type="bibr">3</xref>). Tumor immunosurveillance relies on traits of malignant transformation that can be recognized by innate and adaptive immune cells. As oncogenic stress induces the upregulation of ligands for activating NK cell receptors (<xref rid="B4" ref-type="bibr">4</xref>) and other immune stimulatory surface molecules, tumor cells can be recognized and rejected by NK cells. This innate immune response can further activate a targeted adaptive immune response against antigens specifically expressed by lysed tumor cells and thereby lead to T cell dependent tumor control. Such immunogenic antigens are either highly overexpressed in tumor cells or even tumor specific (when caused by non-silent mutations that have accumulated during malignant transformation) (<xref rid="B5" ref-type="bibr">5</xref>). Whole genome sequencing data from lung cancer (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>), melanoma, and lymphoblastoid carcinoma (<xref rid="B8" ref-type="bibr">8</xref>) genomes indicate that tumors can harbor up to 50,000 somatic mutations of which few hundreds affect protein-coding sequences. It is estimated that this will result in about 7&#x02013;10 new and unique MHC-binding peptides per HLA allele (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Accordingly, innate immunity may constitute a first line of defense, but long-term control is thought to depend on the subsequent adaptive immune responses and on memory cells, which also provide us with life-long protection against pathogens. The detailed roles of different immune cells in tumor immunosurveillance have been comprehensively reviewed recently (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>).</p><p>Key molecules for tumor immunosurveillance as identified in knockout mouse models comprise interferon-&#x003b3; (IFN&#x003b3;) (<xref rid="B12" ref-type="bibr">12</xref>), IL-12 (<xref rid="B13" ref-type="bibr">13</xref>) perforin (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>), TRAIL (tumor necrosis factor related apoptosis-inducing ligand) (<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>), and its corresponding apoptosis-inducing receptors DR4 and DR5 (<xref rid="B20" ref-type="bibr">20</xref>), the recombination activating genes RAG1 (<xref rid="B21" ref-type="bibr">21</xref>), and RAG2 (<xref rid="B12" ref-type="bibr">12</xref>), which are required for T cell development, the T cell receptor (<xref rid="B22" ref-type="bibr">22</xref>), and the activating NK cell receptor NKG2D (<xref rid="B23" ref-type="bibr">23</xref>). The loss of any of these molecules results in more frequent or faster spontaneous or carcinogen-induced tumorigenesis. The ability to evade immune destruction was thus recognized as an additional hallmark of cancer (<xref rid="B24" ref-type="bibr">24</xref>).</p></sec><sec id="S2"><title>Tumor Latency and Immune Escape</title><p>Late recurrence indicates that tumor outgrowth can sometimes be constrained over decades. Koebel et al. (<xref rid="B13" ref-type="bibr">13</xref>) elegantly demonstrated that the immune system can control tumor outgrowth without actually eradicating every malignant cell. By treating immunocompetent mice with low doses of the carcinogenic compound methylcholanthrene, they induced stable masses containing only very few malignantly transformed cells. However, when CD4<sup>+</sup> or CD8<sup>+</sup> T cells were depleted even as late as 200&#x02009;days after chemical carcinogenesis, tumors started to grow. This indicates that the immune system can control tumor growth and keep pre-malignant lesions in a dormant state rather than completely eliminating every transformed cell.</p><p>Correspondingly, immunocompromised humans such as recipients of organ transplants (<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>) or AIDS patients (<xref rid="B29" ref-type="bibr">29</xref>&#x02013;<xref rid="B31" ref-type="bibr">31</xref>) have a significantly increased risk of cancer development, which may be partially attributed to the loss of immunological control over preexistent malignantly transformed cells. Advanced age remains the most important risk factor for tumor development [recently reviewed by de Magalhaes (<xref rid="B32" ref-type="bibr">32</xref>)], which may be due to a decline of immunosurveillance. While the stochastic increase in the number of genetic alterations over time and the deterioration of cellular repair mechanisms certainly contribute to this well-known phenomenon, age-dependent defects in the immune system (also termed &#x0201c;immunosenescence&#x0201d;) (<xref rid="B33" ref-type="bibr">33</xref>&#x02013;<xref rid="B35" ref-type="bibr">35</xref>) are also likely to facilitate tumor outgrowth. This is corroborated by the finding that adoptively transferred spleen cells from young immunized mice eliminate even large tumors whereas immune cells from old mice are not protective (<xref rid="B36" ref-type="bibr">36</xref>). Further factors which may reduce the efficiency of anti-tumor immune responses include non-recognition of tumor antigens due to pre-established tolerance (<xref rid="B37" ref-type="bibr">37</xref>), evolution of poorly immunogenic subsets of tumor cells and immunosuppression via accessory cells in the tumor microenvironment. However, tumor-initiating cells need to escape from immunosurveillance even before a proper tumor microenvironment has been established.</p><p>On cellular level, continuous genetic transformation can randomly generate less-immunogenic malignant subclones. Lower levels of activatory and/or higher levels of inhibitory NK cell receptor ligands (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>) may enable these cells to survive in the presence of the immune system. Also antigens toward which a specific T cell immune response has been established may be lost (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Furthermore, aggressive tumors are often characterized by low levels of classical HLA class I molecules. Accordingly, those tumor antigens, which are expressed, are poorly presented which limits killing by CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) (<xref rid="B42" ref-type="bibr">42</xref>). Nevertheless, a complete loss of &#x0201d;self-MHC,&#x0201d; which would render cells most susceptible for NK cell killing (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B45" ref-type="bibr">45</xref>) does not seem to be the rule. A further important aspect is the active suppression of NK and T cells in the tumor microenvironment where immunosuppressive cytokines or hormones are abundant. Cell surface expression and/or secretion of immune-inhibitory non-classical HLA class I molecules such as HLA-G and HLA-E also contributes to local immune paralysis (<xref rid="B42" ref-type="bibr">42</xref>).</p><p>Physiologically, many of these factors are required for feto-maternal immune tolerance. As immune-mediated destruction of semi-allogeneic embryonic cells would preclude a successful pregnancy, tolerance toward cells expressing &#x0201c;non-self&#x0201d; antigens is essential for reproduction. This imposes certain limits to the stringent elimination of altered cells. Unfortunately, the same tolerance inducing strategies may also be used by cancer cells to overcome immunosurveillance. Nevertheless, mechanisms to prevent tumor growth still fulfill their evolutionary purpose by largely protecting individuals from cancer until reproductive age or, ideally, until their children (or even grandchildren) have become adults.</p></sec><sec id="S3"><title>Introduction to Cancer Stem Cells</title><p>Tissue-specific stem cells have been described in many tissues prone to cancer, including breast (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>), lung (<xref rid="B48" ref-type="bibr">48</xref>), prostate (<xref rid="B49" ref-type="bibr">49</xref>&#x02013;<xref rid="B51" ref-type="bibr">51</xref>), intestine (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>), and many others. They are exceptionally long-lived and can perpetually self-renew. They further give rise to progenitor cells, which are more restricted in their developmental potential, but capable of undergoing rapid cell divisions. The respective daughter cells then further differentiate into mature tissue-specific cells, which contribute to growth, tissue homeostasis, and wound healing (Figure <xref ref-type="fig" rid="F1">1</xref>A) [reviewed by Ref. (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>)].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Stem cells and progenitor cells in tissue homeostasis, tumorigenesis, and tumor recurrence</bold>. <bold>(A)</bold> During organogenesis or in response to tissue damage, resting stem cells (SCs) are induced to undergo asymmetric divisions that produce further differentiated progenitor cells (PCs). Progenitor cells can quickly regenerate tissue by first undergoing a limited number of symmetric cell divisions. The generated daughter cells can then further differentiate to acquire organ-specific functions while generally losing the ability to reenter the cell cycle. <bold>(B)</bold> Stem cells are exceptionally long-lived, pluripotent, and can undergo an unlimited number of cell divisions. Therefore, they may accumulate more mutations than other cells and are thus stochastically more likely to initiate a tumor. These mutations are passed on to progenitor cells, which may drive tumor outgrowth as they cycle much faster by nature. <bold>(C)</bold> Stem cells and CSCs are highly resistant to chemotherapeutic agents and irradiation, which explains why these cells might selectively survive cytoreductive therapy. Therefore, these cells may cause cancer recurrence years or decades later.</p></caption><graphic xlink:href="fimmu-05-00360-g001"/></fig><p>This cellular hierarchy within a tissue has been studied most extensively in the hematopoietic system. Here, long term and short term stem cells, multipotent and lineage-committed progenitor cells, precursors, and fully differentiated cells have been well characterized based on their functional properties and on cell surface markers [reviewed by Orkin (<xref rid="B56" ref-type="bibr">56</xref>)]. Among these, pluripotent stem cells tend to cycle very slowly while the bulk of blood cells originate from various frequently dividing progenitor cell populations (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>). In adult mice, a population of quiescent or dormant hematopoietic stem cells has been described to undergo only about five divisions during the lifespan of a mouse (<xref rid="B59" ref-type="bibr">59</xref>).</p><p>Because of their longevity, pluripotency, and seemingly unlimited potential to undergo cell divisions, stem cells have long been suspected to be the culprits for tumor formation (<xref rid="B60" ref-type="bibr">60</xref>). It is indeed much more likely that a stem cell, which persists for decades in a given tissue, rather than a short-lived differentiated cell, can accumulate numerous mutations as required for malignant transformation (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>) (Figures <xref ref-type="fig" rid="F1">1</xref>B and S1 in Supplementary Material). Moreover, the presence of highly diverse cancer cell populations both in tumors and metastases indicates that their cells of origin are pluripotent. In fact, Kleinsmith and colleagues showed already in the 1960s that some teratocarcinoma cells are capable of seeding highly heterogeneous tumors even if only single cells are transplanted (<xref rid="B63" ref-type="bibr">63</xref>). Recently, it was shown that even some blood vessels within glioblastoma are derived from tumor cells (<xref rid="B64" ref-type="bibr">64</xref>). This strikingly illustrates the remaining differentiation potential of tumor-initiating cells.</p><p>Clinical observations from cancer patients teach us that tumor recurrence may still occur years or decades after a successful-appearing treatment. In this context, a recent sequencing study on acute myeloid leukemia showed that cells collected at the time of the initial diagnosis and during relapse were both closely related to stem cells. Surprisingly, cells collected after relapse had often undergone fewer cell divisions than cells collected at first diagnosis (<xref rid="B65" ref-type="bibr">65</xref>). This suggests that the relapsed disease originated from Cancer stem cells (CSCs), which had been largely quiescent during the initial tumor burst, but which survived tumor eradication without losing their malignant potential. Indirectly, this also confirms the existence of a long-lived and multipotent subpopulation of cancer cells, which is highly resistant to radio- and chemotherapy (Figure <xref ref-type="fig" rid="F1">1</xref>C) and too small to be detected by common screening methods.</p><p>Similar to non-malignant stem cells, CSCs are thought to cycle much more slowly than cancer progenitor cells (CPCs). This could explain their resistance toward drugs directed against dividing cells. Additionally, many stem cells can minimize intracellular drug levels via expression of ABC (ATP binding cassette) transporters (<xref rid="B66" ref-type="bibr">66</xref>). Accordingly, chemoresistance is expected to be an inherent trait of CSC even before the onset of therapy. Furthermore, stem cells and cancer cells share decreased p53 activity and increased telomerase activity (<xref rid="B67" ref-type="bibr">67</xref>).</p><p>Still, resistant CSCs are not necessarily the main drivers of rapid tumor outgrowth. While acquisition of specific mutations may alter the replicative behavior of these quiescent and niche-dependent cells (<xref rid="B68" ref-type="bibr">68</xref>), homeostatic, and presumably also neoplastic tissue growth depends mainly on niche-independent progenitor cells which divide much more rapidly. In this manuscript, the term CPC is used for the malignant counterparts of such rapidly dividing and lineage-committed cells. As these cells inherit genomic mutations accumulated by stem cells, malignantly transformed stem cells will give rise to malignantly transformed committed progenitor cells, which can then drive tumor growth. Luminal progenitor cells deleted for the tumor suppressor gene Brca1 were thus shown to seed basal-like breast cancer in mice (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B70" ref-type="bibr">70</xref>). Likewise, prostate cancer can be initiated by basal progenitor cells, which have been virally transfected with oncogenes (<xref rid="B71" ref-type="bibr">71</xref>). Obviously, CPCs may not only inherit mutations, but also accumulate &#x0201c;first genetic hits,&#x0201d; which likely contributes to clonal evolution and to the heterogeneity typically found in late stage tumors.</p></sec><sec id="S4"><title>The Cancer Stem Cell Hypothesis &#x02013; Ambiguities and Criticism</title><p>Cellular differentiation states are difficult to categorize. While omnipotent embryonic stem cells (ESCs) and terminally differentiated cells represent the two ends of the spectrum, numerous gradual transitions exist in between. Defining clear-cut categories is even more difficult in the tumor context where cellular functions and markers may be randomly altered due to mutations. Distinct stem cell markers have been described for CSCs, but these only help to define CSCs within a certain tissue. In an attempt to define the unifying functional characteristics of a CSC, a panel at the American Association of Cancer Research (AACR) meeting suggested in 2006: &#x0201c;A CSC is a cell within a tumor that possesses the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor&#x0201d; (<xref rid="B72" ref-type="bibr">72</xref>). We consider this definition to be insufficient for several reasons:
<list list-type="simple"><list-item><label>1)</label><p>De-differentiation. By now, a considerable body of evidence indicates that lineage-committed differentiated cells and progenitor cells can de-differentiate into multipotent stem cells. While induced pluripotent stem cells [iPS cells as first introduced by Takahashi and Yamanaka (<xref rid="B73" ref-type="bibr">73</xref>)] are typically generated by artificially introducing defined transcription factors into differentiated cells, de-differentiation can also occur spontaneously (<xref rid="B74" ref-type="bibr">74</xref>) or in response to external stimuli (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>). Accordingly, both tissues and tumors may not be organized in a strictly hierarchical manner with few stem cells on the apex, but rather in a more dynamic way with constantly differentiating and de-differentiating cells (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). Likewise, a fairly constant percentage of CSC-like cells can be found to co-exist with basal or luminal progenitor cells in some established tumor cell lines. These populations can be isolated. However, if cultured for a few days, each of them will regenerate the depleted populations and an equilibrium containing almost identical proportions of all three original differentiation states is quickly reestablished (<xref rid="B77" ref-type="bibr">77</xref>).</p><p>The most prominent example of physiological transdifferentiation is the so-called epithelial to mesenchymal transition (EMT) (<xref rid="B79" ref-type="bibr">79</xref>&#x02013;<xref rid="B81" ref-type="bibr">81</xref>) during which epithelial cells acquire stem cell-like properties. Interestingly, in breast cancer or melanoma EMT can be induced by CD8<sup>+</sup> T cells (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B80" ref-type="bibr">80</xref>). Accordingly, there appears to be more plasticity within the cellular hierarchy than previously anticipated, especially in tumors.</p></list-item><list-item><label>2)</label><p>The frequency of tumor-propagating cells depends on the respective animal model. For melanoma, CSC markers, frequencies, and their role in tumorigenesis were investigated in considerable detail. CD20 (<xref rid="B82" ref-type="bibr">82</xref>), CD133 (<xref rid="B83" ref-type="bibr">83</xref>), ABCG2 (<xref rid="B83" ref-type="bibr">83</xref>), MDR1 (<xref rid="B84" ref-type="bibr">84</xref>), or CD271 (<xref rid="B85" ref-type="bibr">85</xref>) have all been described as potential markers for melanoma cells with increased tumorigenic potential as assessed in non-obese diabetic (NOD)/severe combined immune-deficient (scid) mice. With about one CSC in 10<sup>6</sup> melanoma cells, these CSCs constitute only a minute subset of all tumor cells (<xref rid="B86" ref-type="bibr">86</xref>). However, in a highly debated (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>) article, Quintana et al. (<xref rid="B89" ref-type="bibr">89</xref>) reported that about 27% of highly aggressive melanoma cells were capable of inducing tumors in interleukin-2 receptor gamma chain deficient (Il2rg<sup>&#x02212;/&#x02212;</sup>) NOD/scid (NSG) mice, which do not only lack T and B, but also NK cells. Thus, the proportion of tumor cells, which can self-renew and seed heterogeneous tumors in highly immunodeficient mice may be much higher than previously anticipated. This raised the question whether the small subpopulation of CSCs is of any clinical relevance (<xref rid="B86" ref-type="bibr">86</xref>).</p><p>In a later study, the same authors proposed that most melanoma cells may reversibly express stem cell markers (<xref rid="B90" ref-type="bibr">90</xref>). They argue in favor of clonal evolution and negate any kind of hierarchical organization within a tumor cell population, thus refuting the basic idea underlying the CSC hypothesis. Accordingly, the term CSC is avoided by some authors and replaced by more descriptive alternatives such as cancer-initiating cell, tumor-propagating cell or metastasis-initiating cell. In our opinion, however, this approach has not helped to simplify matters, especially since suitable markers and physiologically correlating cell populations are ill-defined.</p></list-item></list></p><p>We believe that the ability of differentiated cancer cells to de-differentiate into CSCs may partly reconcile these conflicting findings. Moreover, it should be noted that these data were generated in mice with very different immunological properties. Thus, a unique and functionally most relevant criterion shared by stem cells and CSCs, namely their lack of immunogenicity, should be considered.</p></sec><sec id="S5"><title>Immunological Properties of CSCs</title><p>Unfortunately, our knowledge about specific immunological properties of distinct CSC populations is still limited. It is, however, clear that high levels of anti-apoptotic proteins like bcl-2, bcl-xL, or survivin do not only protect CSCs against chemotherapeutic drugs (<xref rid="B91" ref-type="bibr">91</xref>), but also increase resistance toward apoptosis-inducing immune effectors like T or NK cells. In this context, the PI3K/Akt pathway seems to be of particular relevance: it is not only a known mediator of chemoresistance and CSC renewal (<xref rid="B92" ref-type="bibr">92</xref>), but was also found to be involved in tumor immune escape (<xref rid="B93" ref-type="bibr">93</xref>). Likewise, the oncogenic growth factor receptor HER2/neu (which activates PI3K/Akt signaling) does not only deliver pro-survival signals (<xref rid="B94" ref-type="bibr">94</xref>). HER2 does also interfere with antigen processing and presentation (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>) and it was reported as crucial for the maintenance of CSC in luminal breast cancer (<xref rid="B97" ref-type="bibr">97</xref>). Thus, mechanisms which were mainly thought to mediate chemoresistance in CSC may also confer cross protection against immune-mediated tumor eradication.</p><p>In the aggressive melanoma cell line A375, Schatton and Frank also found the immunogenic tumor-associated antigen MART-1 (melanoma antigen recognized by T cells) to be only expressed on differentiated melanoma cells, but not on malignant melanoma initiating cells (MMICs). MART-1-specific T cells thus cannot eliminate MMICs (<xref rid="B98" ref-type="bibr">98</xref>). Reim et al. have further shown that CD44<sup>high</sup>/CD24<sup>low</sup> breast CSCs selectively escape from NK cell mediated killing and trastuzumab-dependent ADCC (<xref rid="B99" ref-type="bibr">99</xref>). While these findings explain the difficulties in targeting CSCs with immune cells, stem cell-like cells are not only poor targets for immunosurveillance. They also actively suppress immune responses (<xref rid="B100" ref-type="bibr">100</xref>), which may be crucial during tumorigenesis (<xref rid="B101" ref-type="bibr">101</xref>). Breast CSCs (<xref rid="B102" ref-type="bibr">102</xref>) and glioblastoma stem cells (<xref rid="B103" ref-type="bibr">103</xref>) secrete more TGF-&#x003b2; as compared to normal tumor cells. Colon CSCs are further known to secrete Interleukin 4 (<xref rid="B104" ref-type="bibr">104</xref>), which promotes drug resistance (<xref rid="B104" ref-type="bibr">104</xref>) and inhibits anti-tumor immune responses (<xref rid="B105" ref-type="bibr">105</xref>). CSCs also express CD200 (<xref rid="B106" ref-type="bibr">106</xref>), a molecule that inhibits myeloid cells and could therefore play a major role in tumor immune escape (<xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B108" ref-type="bibr">108</xref>). Immunological properties of CSCs in solid tumors have also been recently reviewed by Maccalli et al. (<xref rid="B109" ref-type="bibr">109</xref>).</p><p>More is known about molecular immunological properties of physiological stem cells. ESCs express little classical antigen-presenting MHC class Ia molecules and no MHC class II molecules and will thus be poor antigen presenters for T cells. Additionally, they express only low levels of ligands for the activatory NK cell receptor NKp44 and no ligands for NKp30, NKp46, and CD16 (<xref rid="B110" ref-type="bibr">110</xref>). Among inhibitory signals, HLA-G (<xref rid="B111" ref-type="bibr">111</xref>) is highly expressed by both embryonic (<xref rid="B112" ref-type="bibr">112</xref>) and mesenchymal stem cells (MSCs) (<xref rid="B113" ref-type="bibr">113</xref>). Thus, studies describing higher MHC class I expression on stem cells may have failed to distinguish between immunogenic MHC class Ia (HLA-A, -B, -C) and immunosuppressive MHC class Ib (HLA-E, -F, -G) molecules. MHC class II or costimulatory molecules such as CD40, B7-1 (CD80), or B7-2 (CD86), which can also support T cell interactions with non-lymphoid cells (<xref rid="B114" ref-type="bibr">114</xref>) have not been found on MSCs (<xref rid="B115" ref-type="bibr">115</xref>&#x02013;<xref rid="B117" ref-type="bibr">117</xref>).</p><p>T cell proliferation, macrophage activation, and Th1 responses can further be suppressed by prostaglandin E2 (PGE2), which is secreted by MSCs (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>). After exposure to IFN-&#x003b3;, MSCs also upregulate indoleamine 2,3-dioxygenase (IDO), which metabolizes tryptophan into immunosuppressive kynurenines. The concomitant tryptophan depletion also has a profound inhibiting effect on T cells (<xref rid="B120" ref-type="bibr">120</xref>). Via secretion of hepatocyte growth factor (<xref rid="B121" ref-type="bibr">121</xref>), MSCs can further induce tolerogenic dendritic cells and regulatory T cells (<xref rid="B122" ref-type="bibr">122</xref>). Consequently, MSCs show beneficial effects in autoimmune disease models (<xref rid="B123" ref-type="bibr">123</xref>&#x02013;<xref rid="B125" ref-type="bibr">125</xref>).</p><p>To summarize, stem cells and CSCs both express numerous and diverse membrane-bound and soluble factors (Figure <xref ref-type="fig" rid="F2">2</xref>), which enable these cells to efficiently modulate immune responses and which protect them against immune-mediated destruction in a way that is unrivaled by further or fully differentiated cells. Strikingly, mouse ESCs and human MSCs have even been shown to survive for weeks and to engraft in immunocompetent rats (<xref rid="B126" ref-type="bibr">126</xref>) and sheep (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>). The immunomodulatory potential of MSCs is now exploited clinically to counteract graft-versus-host disease (<xref rid="B129" ref-type="bibr">129</xref>) and to promote allograft acceptance upon solid organ transplantation (<xref rid="B130" ref-type="bibr">130</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Factors and pathways contributing to the low immunogenicity of stem cells and CSCs</bold>. Membrane-bound (solid line) and soluble factors (dotted lines) implicated in immunotolerance toward stem cells and CSCs are schematically depicted. These include antigen-presenting and immunostimulatory molecules (orange) expressed at low levels and abundantly expressed immunosuppressive factors (blue) (see main text for references). Immune effector cells impaired by these signals are shown in red whereas tolerogenic immune cells, which may be stimulated are displayed in green.</p></caption><graphic xlink:href="fimmu-05-00360-g002"/></fig><p>As the immune system is incapable of eliminating allogeneic or even xenogenic stem cells, the comparatively few mutations acquired by CSC are unlikely to cause immune-mediated rejection. Thus, stem cells likely represent a unique compartment in which oncogenic mutations can accumulate without being detected by the immune system.</p></sec><sec id="S6"><title>Immune Privilege &#x02013; The Missing CSC Criterion?</title><p>The question whether or not all cancer cells are equally capable of seeding tumors obviously depends also on their ability to escape from destruction by the innate or adaptive immune system. This essential difference, however, may not be observable in a mouse model lacking functional T, B, and NK cells, such as the NSG (<xref rid="B131" ref-type="bibr">131</xref>) mice used by Quintana et al. (<xref rid="B89" ref-type="bibr">89</xref>). The conflicting data on the frequency of melanoma initiating cells can thus easily be explained by accepting that CSCs are much less sensitive toward tumor immunosurveillance than more differentiated cells. While NK cells in NOD/scid mice may clear more differentiated cancer cells (Figure <xref ref-type="fig" rid="F3">3</xref>B), they cannot eliminate immunosubversive human CSCs (Figure <xref ref-type="fig" rid="F3">3</xref>A). Thus, non-CSC-like cancer cells may replicate endlessly <italic>in vitro</italic> whereas only CSCs will seed tumors in these mice. NK cell-deficient NSG mice can, in contrast, neither eliminate CSCs (Figure <xref ref-type="fig" rid="F3">3</xref>C) nor more differentiated cancer cells, which would then also become capable of seeding tumors (Figure <xref ref-type="fig" rid="F3">3</xref>D). Their recently discovered ability to de-differentiate may then further facilitate tumor propagation.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Tumor-propagating capacity depends on immunological properties of injected cancer cells and on the respective mouse model</bold>. NK cells in NOD/scid mice are likely incapable of eliminating CSCs due to their low immunogenicity <bold>(A)</bold>. More differentiated cancer cells expressing ligands for activating NK cell receptors and fewer immunosuppressive molecules may, however, be recognized and eliminated by host NK cells <bold>(B)</bold>. In NOD/scid IL2rg<sup>&#x02212;/&#x02212;</sup> (NSG) mice, which also lack NK cells, both poorly immunogenic CSCs <bold>(C)</bold> and further differentiated cancer cells <bold>(D)</bold> can seed tumors, as malignant progenitor cells may also possess enormous proliferative capacity.</p></caption><graphic xlink:href="fimmu-05-00360-g003"/></fig><p>A maximally immune-deficient mouse may therefore demonstrate the malignant potential of differentiated cancer cells in the complete absence of immunosurveillance, an aspect that may have been underestimated in the original CSC theory. We, however, wonder how relevant NSG mice can be for understanding tumor initiation (and thus tumor-initiating cells) in patients. While stem cell experts tend to favor the most completely immunodeficient animal model available, the most relevant subject of translational cancer research is the immune-competent human subject afflicted by a malignant disease. The ability to propagate tumors should therefore best be tested in models possessing a functional immune system. Furthermore, as implied by studies performed in NOD/scid mice (<xref rid="B132" ref-type="bibr">132</xref>&#x02013;<xref rid="B134" ref-type="bibr">134</xref>), the ability to continuously seed tumors in presence of (residual) immunosurveillance may be a most relevant functional criterion for CSCs.</p><p>Consequently, tumor initiation may better be analyzed in congenic or syngenic animals rather than in immunodeficient xenograft models. Limitations arise from the fact that all cells contained in transplantable syngenic tumor cell lines have evidently undergone immunoediting <italic>in vivo</italic> before the cell line could be derived. Accordingly, the proportion of immune-refractory, tumor-seeding cells may be quite variable: with B cell lymphoma cells, for example, inoculation with 10 unsorted cells was sufficient to induce lethal lymphomas within a few weeks, irrespective of expression of the stem cell marker CD93 (<xref rid="B135" ref-type="bibr">135</xref>). In the 4T1 mammary carcinoma cell line, however, exclusion of the stem cells (Hoechst 33342 side population) by cell sorting greatly reduced both tumor take and tumor load, and most animals injected with 8&#x02009;&#x000d7;&#x02009;10<sup>3</sup> non-CSC remained tumor-free (<xref rid="B136" ref-type="bibr">136</xref>). Thus, the frequency of CSCs can differ widely depending on the respective tumor.</p></sec><sec id="S7"><title>Tumor Immunoediting &#x02013; The Model and Unresolved Questions</title><p>The immune privilege of CSCs may not only be relevant for the quantification of tumor-propagating cells, but could also help to elucidate ambiguities in tumor initiation and immune escape. The complex interactions between tumors and the immune system have been described by a model which differentiates between three phases of tumor immunoediting: elimination, equilibrium, and escape (<xref rid="B137" ref-type="bibr">137</xref>). There is now solid scientific evidence for the existence of all three phases and this model nicely correlates with clinical observations (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>During the elimination phase, tumors may be successfully detected and destroyed by the innate and adaptive immune system, which results in the reestablishment of healthy tissue. If, however, some tumor cells escape from elimination, a dynamic equilibrium between tumor growth and immunological elimination of malignant cells was proposed to emerge. While tumor outgrowth is still constrained, elimination of tumor cells remains incomplete, which allows for mutational diversification and Darwinian selection to occur. This latency phase may persist for decades and may be functionally similar to tumor dormancy, the time between an initially successful anti-tumor therapy and tumor recurrence, which can also span decades (<xref rid="B138" ref-type="bibr">138</xref>). When ultimately one clone arises that is capable of escaping from a functional immune system, it may form a clinically overt tumor and initiate the escape phase.</p><p>However, for the equilibrium to be reached, this model requires &#x0201c;not yet immunoedited&#x0201d; cancer cells to survive the early elimination phase. Furthermore, it is not clear why cells, which can be immunologically constrained in equilibrium for decades, are not simply cleared by an adaptive immune response. Normally, expanded and activated CTLs efficiently eliminate cells expressing their cognate antigen whereas cells that have lost all immunologically relevant antigens could directly grow into overt tumors.</p><p>Based on these considerations, latency requires the existence of a poorly immunogenic sub-pool of cancer cells, which escape from targeted immune responses, which can give rise to new cancer cells, but which are initially incapable of growing into massive tumors. Instead, these cells apparently persist for months, years, or even decades within tissues as dormant tumor cells. In our opinion, multipotent stem cells and CSCs, which are not only long-lived, but also exceptionally well protected from immune-mediated destruction, and largely confined to stem cell niches (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B139" ref-type="bibr">139</xref>), would meet all these criteria. By considering the immunological properties of CSCs, a new refined concept of tumor immunoediting can thus be proposed (Figure <xref ref-type="fig" rid="F4">4</xref> and more detailed in Figure S1 in Supplementary Material).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Proposed role of CSCs in tumor immune escape</bold>. Elimination (Left): malignant transformation requires oncogenic mutations (flash) to accumulate within an individual cell. If such mutations occur in a differentiated cell, this cell will upregulate activatory NK cell receptor ligands and present tumor-specific peptides via MHC class Ia molecules (both orange). Thus, these cells can be detected and eliminated by the immune system, leading to restoration of normal tissue. Equilibrium (Center): stem cells (SC) are long-lived and express a multitude of immunosuppressive factors (dark purple). Hence, they may accumulate oncogenic mutations without being cleared by the immune system. However, CSCs are initially confined to stem cell niches (green) and limited to asymmetric divisions. More differentiated daughter cells inherit all malignant mutations, but are more immunogenic and could thus be eliminated by the adaptive immune system. Thus, a robust equilibrium may emerge. Escape (Right): mechanisms contributing to tumor immune escape include defects in tumor immunosurveillance, immunoediting, or the expansion of CSCs. The immune system may lose its ability to constrain tumors due to aging, immunosuppressive therapies, diseases or other factors. Immunoediting describes the evolutionary adaptation of individual tumor subclones to the selection pressure exerted by the immune system. It will ultimately lead to expansion of less-immunogenic or more immunosuppressive subclones. Non-immunogenic CSCs may further acquire the ability to expand independently of their niches, which may lead to the outgrowth of poorly differentiated tumors.</p></caption><graphic xlink:href="fimmu-05-00360-g004"/></fig></sec><sec id="S8"><title>Implementing CSCs in the Concept of Tumor Immunoediting</title><p>When oncogenic mutations occur in fully or partially differentiated cells, activatory NK cell receptor ligands are induced (<xref rid="B4" ref-type="bibr">4</xref>) and tumor antigens are presented via MHC class Ia. Thus, altered cells may be readily detected and eliminated by the immune system. Failure may be due to de-differentiation of mutated cells.</p><p>If, instead, an oncogenic mutation occurs in a poorly immunogenic stem cell, escape from immunosurveillance is much more likely. However, their dependence on stem cell niches may prevent mutated stem cells from growing into overt tumors. Upon asymmetric division, a more differentiated and more immunogenic daughter cell will be generated, which would then be subjected to immunosurveillance. As the other daughter cell will maintain stem cell characteristics, a robust equilibrium would emerge. Recent findings indicate that AML finally arises from such pre-malignant stem cells (<xref rid="B140" ref-type="bibr">140</xref>).</p><p>During this latency period, stochastic genetic and epigenetic changes may accumulate within the reservoir of non-immunogenic stem cells. Mutations in coding regions may generate new immunogenic peptides that would be presented on MHC molecules of malignant daughter cells. Such neoantigens may support immunosurveillance by providing further tumor antigens and, ideally, enabling tumor clearance. However, if CSCs are not eliminated by the immune system, the low frequency of niche-confined, mutated stem cells, and their low rate of cell divisions would still prevent the formation of a clinically relevant tumor as long as their daughter cells are subjected to immunosurveillance. Accordingly, the immune system could constrain a sub-clinical malignant disease in life-long equilibrium.</p><p>However, once tumors become clinically apparent immunosurveillance has failed. This can be due to a weakening of the immune system caused by aging, to therapeutic immunosuppression or to disease. In this case, also moderately immunogenic tumor cells may propagate. Alternatively, cancer cells may actively attenuate immunosurveillance (immunosubversion) by secretion or expression of immunosuppressive factors (<xref rid="B11" ref-type="bibr">11</xref>) or by recruitment of accessory cells, which locally suppress the immune system (<xref rid="B141" ref-type="bibr">141</xref>, <xref rid="B142" ref-type="bibr">142</xref>). Furthermore, genetic alterations may result in reduced expression of antigens that are targeted by the immune system (immunoselection). Other factors allowing for the rapid growth of more differentiated cancer cells include the loss of the antigen processing and presentation machinery (<xref rid="B143" ref-type="bibr">143</xref>) or the loss or shedding of ligands for activatory NK cell receptors (<xref rid="B144" ref-type="bibr">144</xref>). Importantly, non-immunogenic long-lived CSCs provide an evolutionary playground for mutations to accumulate until an immune escape phenotype has emerged.</p><p>Expansion of immune-evasive CSCs represents a further possibility for immune escape. This mechanism may predominate in poorly differentiated tumors, which tend to be more aggressive and more difficult to treat (<xref rid="B145" ref-type="bibr">145</xref>). Alterations in cell signaling pathways are known to enable CSCs to grow outside of their niches (<xref rid="B68" ref-type="bibr">68</xref>). Interestingly, signals that promote stem cell self-renewal and expansion (<xref rid="B146" ref-type="bibr">146</xref>) are also frequently activated in cancer as evidenced by alterations in the notch, wnt, and sonic hedgehog pathways (<xref rid="B147" ref-type="bibr">147</xref>&#x02013;<xref rid="B149" ref-type="bibr">149</xref>).</p><p>Oncogenic mutations may also increase the frequency of cell divisions in otherwise fairly quiescent stem cells (<xref rid="B150" ref-type="bibr">150</xref>) or inhibit differentiation in the respective daughter cells (<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>). Furthermore, CSC proliferation may be promoted by conditions like chronic inflammation, which triggers physiological stem cell division. As these mechanisms are not mutually exclusive, increased cell division in CSCs will also increase the risk for emergence of less-immunogenic and more aggressive subclones.</p></sec><sec id="S9"><title>Implications of &#x0201c;Cancer Stem Cell Immunology&#x0201d;</title><p>Stem cell research has helped to understand tumor initiation, heterogeneity, and drug resistance, while immunological knowledge has provided a framework for apprehending mechanisms that naturally limit tumor growth. Consolidating insights from these two different scientific fields may further help to explain phenomena which are still poorly understood.</p><p>As discussed in this opinion article, we propose that pluripotency, immortality, and an apparently unlimited potential to undergo cell divisions may be insufficient criteria for distinguishing CSCs from other cancer cells. In the tumor context, partly differentiated cells may also acquire these properties through mutations or de-differentiation processes. However, the unique immunological properties of stem cells and CSCs may help to further discriminate these cells from the tumor bulk (Table <xref ref-type="table" rid="T1">1</xref>). Experimental evidence supporting this novel perspective may be drawn from model-dependent differences regarding the respective frequencies of tumor-initiating cells. This may best be explained by considering the different levels of immunogenicity coexisting within the same tumor. In addition, CSCs excellently complement current models of tumor immune escape. They can be seen as highly resistant and long-lived units of Darwinian selection, which accumulate mutations and undergo immunoediting over decades. Thus, they can either remain dormant or represent an almost invincible backbone of tumorigenesis which links &#x0201c;the three <italic>e</italic>&#x02019;s of cancer immunoediting&#x0201d;: elimination, equilibrium, and escape, i.e., tumor recurrence.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>A grossly schematic overview summarizing characteristic properties and functions of stem cells, progenitor cells, and differentiated cells and their malignant counterparts</bold>.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1"><inline-graphic xlink:href="fimmu-05-00360-i001.jpg"/></td></tr></tbody></table><table-wrap-foot><p><italic>Properties promoting tumor growth are shaded in red whereas traits that limit the malignant potential are highlighted in green. Though the actual characteristics vary significantly between different tissues and tumors, common tendencies were sought. Some selected references are provided, and more are given in the main body of the manuscript. When no representative reference could be found in the literature, this variability is indicated (var.). Where no data were available, an estimate is given (CSC, cancer stem cell; CPC, cancer progenitor cell; diff. CC, differentiated cancer cell)</italic>.</p></table-wrap-foot></table-wrap><p>Yet what are the clinical implications if CSCs are not only highly resistant to chemo- and radiotherapy (<xref rid="B153" ref-type="bibr">153</xref>) but also to anti-tumor immune responses? Strategies to specifically target CSCs for elimination (<xref rid="B154" ref-type="bibr">154</xref>, <xref rid="B155" ref-type="bibr">155</xref>) or to induce differentiation (<xref rid="B156" ref-type="bibr">156</xref>) would obviously be most desirable. However, none of the current approaches shows a high selectivity for CSCs over non-malignant stem cells. Therefore, therapies that efficiently and selectively eliminate CSCs are still far from clinical application. Still, accepting that we are currently unable to eradicate CSCs is far from accepting defeat in the war on cancer. Instead, by accepting these limitations one can rather prioritize strategies, which are more likely to work. These include, on the one hand, the indirect targeting of CSC via the tumor stroma, which represents a niche for CSCs (<xref rid="B157" ref-type="bibr">157</xref>&#x02013;<xref rid="B160" ref-type="bibr">160</xref>). On the other hand, containment and control of CSCs to maintain tumors in the equilibrium phase may be a realistic clinical aim. This, however, depends on the incessant functionality of the immune system (<xref rid="B161" ref-type="bibr">161</xref>). Beneficial effects of radio- or chemotherapy, which can destroy some tumor cells (but presumably not the CSC) may thus largely depend on immune responses induced by provision of danger signals and by liberation of antigens from damaged tumor cells (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>). Strengthening of cancer immunosurveillance by vaccination strategies or by directly activating the immune system (<xref rid="B164" ref-type="bibr">164</xref>&#x02013;<xref rid="B166" ref-type="bibr">166</xref>) may support such a response and thus be effective in preventing tumor recurrence over prolonged periods of time (<xref rid="B167" ref-type="bibr">167</xref>, <xref rid="B168" ref-type="bibr">168</xref>). Adjuvant immunotherapy might hence be advisable when a successful-appearing treatment has reduced overt cancer to minimal residual disease (which likely represents an immunologically sustained equilibrium). Overaggressive treatment modalities are, however, strongly immunosuppressive and may be detrimental. In fact, a comparatively mild metronomic chemotherapy may often be more effective (<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>) than application of the maximum tolerated dose, which still fails to eliminate the seed of the evil but enables the outgrowth of more differentiated malignant cells. Assuming that CSCs represent moving targets, which need to be controlled throughout the whole life, we need to learn how the highly dynamic and adaptable forces of our immune system can best be used in the war on cancer. Fortunately, first studies are showing the potential of cancer immunotherapy in clinical reality.</p><p>Last but not least, an improved understanding of the mechanisms which enable either tumor control or escape may help to devise suitable therapeutic strategies. We thus hope that the still speculative, but hopefully coherent conceptual framework outlined in this brief article will stimulate further research in &#x0201c;CSC immunology.&#x0201d; In the best case, a mutual exchange of ideas could not only inspire both the CSC and the tumor immunology community, but eventually also lead to some benefit for patients who depend on a wisely chosen therapy.</p></sec><sec id="S10"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="supplementary-material" id="S11"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at <uri xlink:type="simple" xlink:href="http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00360/abstract">http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00360/abstract</uri></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Presentation_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>Valentin S. Bruttel was supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of W&#x000fc;rzburg.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lodish</surname><given-names>HBA</given-names></name><name><surname>Matsudaira</surname><given-names>P</given-names></name><name><surname>Kaiser</surname><given-names>CA</given-names></name><name><surname>Krieger</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>MP</given-names></name><name><surname>Zipursky</surname><given-names>SL</given-names></name><etal/></person-group>
<source>Molecular Biology of the Cell</source>. <edition>5th ed</edition>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>WH Freeman</publisher-name> (<year>2004</year>).</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group>
<article-title>The hallmarks of cancer</article-title>. <source>Cell</source> (<year>2000</year>) <volume>100</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id><pub-id pub-id-type="pmid">10647931</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnet</surname><given-names>FM</given-names></name></person-group>
<article-title>The concept of immunological surveillance</article-title>. <source>Prog Exp Tumor Res</source> (<year>1970</year>) <volume>13</volume>:<fpage>1</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="pmid">4921480</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raulet</surname><given-names>DH</given-names></name><name><surname>Guerra</surname><given-names>N</given-names></name></person-group>
<article-title>Oncogenic stress sensed by the immune system: role of natural killer cell receptors</article-title>. <source>Nat Rev Immunol</source> (<year>2009</year>) <volume>9</volume>(<issue>8</issue>):<fpage>568</fpage>&#x02013;<lpage>80</lpage><pub-id pub-id-type="doi">10.1038/nri2604</pub-id><pub-id pub-id-type="pmid">19629084</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haen</surname><given-names>SP</given-names></name><name><surname>Rammensee</surname><given-names>HG</given-names></name></person-group>
<article-title>The repertoire of human tumor-associated epitopes &#x02013; identification and selection of antigens and their application in clinical trials</article-title>. <source>Curr Opin Immunol</source> (<year>2013</year>) <volume>25</volume>(<issue>2</issue>):<fpage>277</fpage>&#x02013;<lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2013.03.007</pub-id><pub-id pub-id-type="pmid">23619309</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleasance</surname><given-names>ED</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>O&#x02019;Meara</surname><given-names>S</given-names></name><name><surname>McBride</surname><given-names>DJ</given-names></name><name><surname>Meynert</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>A small-cell lung cancer genome with complex signatures of tobacco exposure</article-title>. <source>Nature</source> (<year>2010</year>) <volume>463</volume>(<issue>7278</issue>):<fpage>184</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nature08629</pub-id><pub-id pub-id-type="pmid">20016488</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Haverty</surname><given-names>PM</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Stinson</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>The mutation spectrum revealed by paired genome sequences from a lung cancer patient</article-title>. <source>Nature</source> (<year>2010</year>) <volume>465</volume>(<issue>7297</issue>):<fpage>473</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature09004</pub-id><pub-id pub-id-type="pmid">20505728</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleasance</surname><given-names>ED</given-names></name><name><surname>Cheetham</surname><given-names>RK</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>McBride</surname><given-names>DJ</given-names></name><name><surname>Humphray</surname><given-names>SJ</given-names></name><name><surname>Greenman</surname><given-names>CD</given-names></name><etal/></person-group>
<article-title>A comprehensive catalogue of somatic mutations from a human cancer genome</article-title>. <source>Nature</source> (<year>2010</year>) <volume>463</volume>(<issue>7278</issue>):<fpage>191</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature08658</pub-id><pub-id pub-id-type="pmid">20016485</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>NH</given-names></name><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Peggs</surname><given-names>KS</given-names></name><name><surname>Velculescu</surname><given-names>V</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Epitope landscape in breast and colorectal cancer</article-title>. <source>Cancer Res</source> (<year>2008</year>) <volume>68</volume>(<issue>3</issue>):<fpage>889</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-3095</pub-id><pub-id pub-id-type="pmid">18245491</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vesely</surname><given-names>MD</given-names></name><name><surname>Kershaw</surname><given-names>MH</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group>
<article-title>Natural innate and adaptive immunity to cancer</article-title>. <source>Annu Rev Immunol</source> (<year>2011</year>) <volume>29</volume>:<fpage>235</fpage>&#x02013;<lpage>71</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101324</pub-id><pub-id pub-id-type="pmid">21219185</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group>
<article-title>Cancer despite immunosurveillance: immunoselection and immunosubversion</article-title>. <source>Nat Rev Immunol</source> (<year>2006</year>) <volume>6</volume>(<issue>10</issue>):<fpage>715</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1038/nri1936</pub-id><pub-id pub-id-type="pmid">16977338</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shankaran</surname><given-names>V</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Bruce</surname><given-names>AT</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><etal/></person-group>
<article-title>IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity</article-title>. <source>Nature</source> (<year>2001</year>) <volume>410</volume>(<issue>6832</issue>):<fpage>1107</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1038/35074122</pub-id><pub-id pub-id-type="pmid">11323675</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koebel</surname><given-names>CM</given-names></name><name><surname>Vermi</surname><given-names>W</given-names></name><name><surname>Swann</surname><given-names>JB</given-names></name><name><surname>Zerafa</surname><given-names>N</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><etal/></person-group>
<article-title>Adaptive immunity maintains occult cancer in an equilibrium state</article-title>. <source>Nature</source> (<year>2007</year>) <volume>450</volume>(<issue>7171</issue>):<fpage>903</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature06309</pub-id><pub-id pub-id-type="pmid">18026089</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Broek</surname><given-names>ME</given-names></name><name><surname>Kagi</surname><given-names>D</given-names></name><name><surname>Ossendorp</surname><given-names>F</given-names></name><name><surname>Toes</surname><given-names>R</given-names></name><name><surname>Vamvakas</surname><given-names>S</given-names></name><name><surname>Lutz</surname><given-names>WK</given-names></name><etal/></person-group>
<article-title>Decreased tumor surveillance in perforin-deficient mice</article-title>. <source>J Exp Med</source> (<year>1996</year>) <volume>184</volume>(<issue>5</issue>):<fpage>1781</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1084/jem.184.5.1781</pub-id><pub-id pub-id-type="pmid">8920866</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Thia</surname><given-names>KY</given-names></name><name><surname>Street</surname><given-names>SE</given-names></name><name><surname>MacGregor</surname><given-names>D</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name></person-group>
<article-title>Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma</article-title>. <source>J Exp Med</source> (<year>2000</year>) <volume>192</volume>(<issue>5</issue>):<fpage>755</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="doi">10.1084/jem.192.5.755</pub-id><pub-id pub-id-type="pmid">10974040</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Cretney</surname><given-names>E</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth</article-title>. <source>Cell Immunol</source> (<year>2001</year>) <volume>214</volume>(<issue>2</issue>):<fpage>194</fpage>&#x02013;<lpage>200</lpage><pub-id pub-id-type="doi">10.1006/cimm.2001.1896</pub-id><pub-id pub-id-type="pmid">12088418</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Cretney</surname><given-names>E</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Kayagaki</surname><given-names>N</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development</article-title>. <source>J Exp Med</source> (<year>2002</year>) <volume>195</volume>(<issue>2</issue>):<fpage>161</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1084/jem.20011171</pub-id><pub-id pub-id-type="pmid">11805143</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cretney</surname><given-names>E</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Glaccum</surname><given-names>M</given-names></name><name><surname>Peschon</surname><given-names>JJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group>
<article-title>Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>168</volume>(<issue>3</issue>):<fpage>1356</fpage>&#x02013;<lpage>61</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.3.1356</pub-id><pub-id pub-id-type="pmid">11801676</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seki</surname><given-names>N</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Brooks</surname><given-names>AD</given-names></name><name><surname>Wine</surname><given-names>J</given-names></name><name><surname>Wiltrout</surname><given-names>RH</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer</article-title>. <source>Cancer Res</source> (<year>2003</year>) <volume>63</volume>(<issue>1</issue>):<fpage>207</fpage>&#x02013;<lpage>13</lpage><pub-id pub-id-type="pmid">12517799</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnberg</surname><given-names>N</given-names></name><name><surname>Klein-Szanto</surname><given-names>AJ</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group>
<article-title>TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis</article-title>. <source>J Clin Invest</source> (<year>2008</year>) <volume>118</volume>(<issue>1</issue>):<fpage>111</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1172/JCI29900</pub-id><pub-id pub-id-type="pmid">18079962</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nepal</surname><given-names>RM</given-names></name><name><surname>Zaheen</surname><given-names>A</given-names></name><name><surname>Basit</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>SA</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name></person-group>
<article-title>AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice</article-title>. <source>Oncogene</source> (<year>2008</year>) <volume>27</volume>(<issue>34</issue>):<fpage>4752</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.111</pub-id><pub-id pub-id-type="pmid">18408759</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girardi</surname><given-names>M</given-names></name><name><surname>Oppenheim</surname><given-names>DE</given-names></name><name><surname>Steele</surname><given-names>CR</given-names></name><name><surname>Lewis</surname><given-names>JM</given-names></name><name><surname>Glusac</surname><given-names>E</given-names></name><name><surname>Filler</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Regulation of cutaneous malignancy by gammadelta T cells</article-title>. <source>Science</source> (<year>2001</year>) <volume>294</volume>(<issue>5542</issue>):<fpage>605</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1126/science.1063916</pub-id><pub-id pub-id-type="pmid">11567106</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>YX</given-names></name><name><surname>Joncker</surname><given-names>NT</given-names></name><name><surname>Choy</surname><given-names>A</given-names></name><name><surname>Gallardo</surname><given-names>F</given-names></name><name><surname>Xiong</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy</article-title>. <source>Immunity</source> (<year>2008</year>) <volume>28</volume>(<issue>4</issue>):<fpage>571</fpage>&#x02013;<lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.016</pub-id><pub-id pub-id-type="pmid">18394936</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group>
<article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source> (<year>2011</year>) <volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>&#x02013;<lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulrich</surname><given-names>C</given-names></name><name><surname>Schmook</surname><given-names>T</given-names></name><name><surname>Sachse</surname><given-names>MM</given-names></name><name><surname>Sterry</surname><given-names>W</given-names></name><name><surname>Stockfleth</surname><given-names>E</given-names></name></person-group>
<article-title>Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients</article-title>. <source>Dermatol Surg</source> (<year>2004</year>) <volume>30</volume>(<issue>4 Pt 2</issue>):<fpage>622</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00042728-200404020-00009</pub-id><pub-id pub-id-type="pmid">15061846</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>F</given-names></name><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Habbab</surname><given-names>F</given-names></name><name><surname>deB Edwardes</surname><given-names>MD</given-names></name><name><surname>Loertscher</surname><given-names>R</given-names></name><name><surname>Meterissian</surname><given-names>S</given-names></name></person-group>
<article-title>Malignancy after renal transplantation: incidence and role of type of immunosuppression</article-title>. <source>Ann Surg Oncol</source> (<year>2002</year>) <volume>9</volume>(<issue>8</issue>):<fpage>785</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF02574501</pub-id><pub-id pub-id-type="pmid">12374662</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andres</surname><given-names>A</given-names></name></person-group>
<article-title>Cancer incidence after immunosuppressive treatment following kidney transplantation</article-title>. <source>Crit Rev Oncol Hematol</source> (<year>2005</year>) <volume>56</volume>(<issue>1</issue>):<fpage>71</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2004.11.010</pub-id><pub-id pub-id-type="pmid">15978827</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vial</surname><given-names>T</given-names></name><name><surname>Descotes</surname><given-names>J</given-names></name></person-group>
<article-title>Immunosuppressive drugs and cancer</article-title>. <source>Toxicology</source> (<year>2003</year>) <volume>185</volume>(<issue>3</issue>):<fpage>229</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0300-483X(02)00612-1</pub-id><pub-id pub-id-type="pmid">12581698</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal Maso</surname><given-names>L</given-names></name><name><surname>Serraino</surname><given-names>D</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name></person-group>
<article-title>Epidemiology of AIDS-related tumours in developed and developing countries</article-title>. <source>Eur J Cancer</source> (<year>2001</year>) <volume>37</volume>(<issue>10</issue>):<fpage>1188</fpage>&#x02013;<lpage>201</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(01)00120-4</pub-id><pub-id pub-id-type="pmid">11423251</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>JJ</given-names></name></person-group>
<article-title>The epidemiology of acquired immunodeficiency syndrome malignancies</article-title>. <source>Semin Oncol</source> (<year>2000</year>) <volume>27</volume>(<issue>4</issue>):<fpage>390</fpage>&#x02013;<lpage>401</lpage><pub-id pub-id-type="pmid">10950365</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bower</surname><given-names>M</given-names></name><name><surname>Palmieri</surname><given-names>C</given-names></name><name><surname>Dhillon</surname><given-names>T</given-names></name></person-group>
<article-title>AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy</article-title>. <source>Curr Opin Infect Dis</source> (<year>2006</year>) <volume>19</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1097/01.qco.0000200295.30285.13</pub-id><pub-id pub-id-type="pmid">16374212</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Magalhaes</surname><given-names>JP</given-names></name></person-group>
<article-title>How ageing processes influence cancer</article-title>. <source>Nat Rev Cancer</source> (<year>2013</year>) <volume>13</volume>(<issue>5</issue>):<fpage>357</fpage>&#x02013;<lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nrc3497</pub-id><pub-id pub-id-type="pmid">23612461</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>L</given-names></name><name><surname>Cristaldi</surname><given-names>E</given-names></name><name><surname>Malaguarnera</surname><given-names>M</given-names></name></person-group>
<article-title>The role of immunity in elderly cancer</article-title>. <source>Crit Rev Oncol Hematol</source> (<year>2010</year>) <volume>74</volume>(<issue>1</issue>):<fpage>40</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2009.06.002</pub-id><pub-id pub-id-type="pmid">19577481</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulop</surname><given-names>T</given-names></name><name><surname>Kotb</surname><given-names>R</given-names></name><name><surname>Fortin</surname><given-names>CF</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name><name><surname>de Angelis</surname><given-names>F</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name></person-group>
<article-title>Potential role of immunosenescence in cancer development</article-title>. <source>Ann N Y Acad Sci</source> (<year>2010</year>) <volume>1197</volume>:<fpage>158</fpage>&#x02013;<lpage>65</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.05370.x</pub-id><pub-id pub-id-type="pmid">20536845</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derhovanessian</surname><given-names>E</given-names></name><name><surname>Solana</surname><given-names>R</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name></person-group>
<article-title>Immunity, ageing and cancer</article-title>. <source>Immun Ageing</source> (<year>2008</year>) <volume>5</volume>:<fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1742-4933-5-11</pub-id><pub-id pub-id-type="pmid">18816370</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>K</given-names></name><name><surname>Arina</surname><given-names>A</given-names></name><name><surname>Engels</surname><given-names>B</given-names></name><name><surname>Spiotto</surname><given-names>MT</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Spleen cells from young but not old immunized mice eradicate large established cancers</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>(<issue>9</issue>):<fpage>2526</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0127</pub-id><pub-id pub-id-type="pmid">22415314</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willimsky</surname><given-names>G</given-names></name><name><surname>Czeh</surname><given-names>M</given-names></name><name><surname>Loddenkemper</surname><given-names>C</given-names></name><name><surname>Gellermann</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Wust</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness</article-title>. <source>J Exp Med</source> (<year>2008</year>) <volume>205</volume>(<issue>7</issue>):<fpage>1687</fpage>&#x02013;<lpage>700</lpage><pub-id pub-id-type="doi">10.1084/jem.20072016</pub-id><pub-id pub-id-type="pmid">18573907</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iguchi-Manaka</surname><given-names>A</given-names></name><name><surname>Kai</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Tahara-Hanaoka</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Accelerated tumor growth in mice deficient in DNAM-1 receptor</article-title>. <source>J Exp Med</source> (<year>2008</year>) <volume>205</volume>(<issue>13</issue>):<fpage>2959</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="doi">10.1084/jem.20081611</pub-id><pub-id pub-id-type="pmid">19029379</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elboim</surname><given-names>M</given-names></name><name><surname>Gazit</surname><given-names>R</given-names></name><name><surname>Gur</surname><given-names>C</given-names></name><name><surname>Ghadially</surname><given-names>H</given-names></name><name><surname>Betser-Cohen</surname><given-names>G</given-names></name><name><surname>Mandelboim</surname><given-names>O</given-names></name></person-group>
<article-title>Tumor immunoediting by NKp46</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>(<issue>10</issue>):<fpage>5637</fpage>&#x02013;<lpage>44</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901644</pub-id><pub-id pub-id-type="pmid">20404273</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>H</given-names></name><name><surname>Vesely</surname><given-names>MD</given-names></name><name><surname>Koboldt</surname><given-names>DC</given-names></name><name><surname>Rickert</surname><given-names>CG</given-names></name><name><surname>Uppaluri</surname><given-names>R</given-names></name><name><surname>Magrini</surname><given-names>VJ</given-names></name><etal/></person-group>
<article-title>Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting</article-title>. <source>Nature</source> (<year>2012</year>) <volume>482</volume>(<issue>7385</issue>):<fpage>400</fpage>&#x02013;<lpage>4</lpage><pub-id pub-id-type="doi">10.1038/nature10755</pub-id><pub-id pub-id-type="pmid">22318521</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuPage</surname><given-names>M</given-names></name><name><surname>Mazumdar</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>LM</given-names></name><name><surname>Cheung</surname><given-names>AF</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group>
<article-title>Expression of tumour-specific antigens underlies cancer immunoediting</article-title>. <source>Nature</source> (<year>2012</year>) <volume>482</volume>(<issue>7385</issue>):<fpage>405</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature10803</pub-id><pub-id pub-id-type="pmid">22318517</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campoli</surname><given-names>M</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name></person-group>
<article-title>Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands</article-title>. <source>Tissue Antigens</source> (<year>2008</year>) <volume>72</volume>(<issue>4</issue>):<fpage>321</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0039.2008.01106.x</pub-id><pub-id pub-id-type="pmid">18700879</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group>
<article-title>The immunobiology of cancer immunosurveillance and immunoediting</article-title>. <source>Immunity</source> (<year>2004</year>) <volume>21</volume>(<issue>2</issue>):<fpage>137</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.07.017</pub-id><pub-id pub-id-type="pmid">15308095</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Emi</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name></person-group>
<article-title>Cancer immunoediting from immune surveillance to immune escape</article-title>. <source>Immunology</source> (<year>2007</year>) <volume>121</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>14</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02587.x</pub-id><pub-id pub-id-type="pmid">17386080</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiman</surname><given-names>JM</given-names></name><name><surname>Kmieciak</surname><given-names>M</given-names></name><name><surname>Manjili</surname><given-names>MH</given-names></name><name><surname>Knutson</surname><given-names>KL</given-names></name></person-group>
<article-title>Tumor immunoediting and immunosculpting pathways to cancer progression</article-title>. <source>Semin Cancer Biol</source> (<year>2007</year>) <volume>17</volume>(<issue>4</issue>):<fpage>275</fpage>&#x02013;<lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2007.06.009</pub-id><pub-id pub-id-type="pmid">17662614</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Vaillant</surname><given-names>F</given-names></name><name><surname>Simpson</surname><given-names>KJ</given-names></name><name><surname>Stingl</surname><given-names>J</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Asselin-Labat</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Generation of a functional mammary gland from a single stem cell</article-title>. <source>Nature</source> (<year>2006</year>) <volume>439</volume>(<issue>7072</issue>):<fpage>84</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature04372</pub-id><pub-id pub-id-type="pmid">16397499</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stingl</surname><given-names>J</given-names></name><name><surname>Eirew</surname><given-names>P</given-names></name><name><surname>Ricketson</surname><given-names>I</given-names></name><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Vaillant</surname><given-names>F</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Purification and unique properties of mammary epithelial stem cells</article-title>. <source>Nature</source> (<year>2006</year>) <volume>439</volume>(<issue>7079</issue>):<fpage>993</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature04496</pub-id><pub-id pub-id-type="pmid">16395311</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CF</given-names></name><name><surname>Jackson</surname><given-names>EL</given-names></name><name><surname>Woolfenden</surname><given-names>AE</given-names></name><name><surname>Lawrence</surname><given-names>S</given-names></name><name><surname>Babar</surname><given-names>I</given-names></name><name><surname>Vogel</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Identification of bronchioalveolar stem cells in normal lung and lung cancer</article-title>. <source>Cell</source> (<year>2005</year>) <volume>121</volume>(<issue>6</issue>):<fpage>823</fpage>&#x02013;<lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.03.032</pub-id><pub-id pub-id-type="pmid">15960971</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>DA</given-names></name><name><surname>Xin</surname><given-names>L</given-names></name><name><surname>Lukacs</surname><given-names>RU</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name></person-group>
<article-title>Isolation and functional characterization of murine prostate stem cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>(<issue>1</issue>):<fpage>181</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1073/pnas.0609684104</pub-id><pub-id pub-id-type="pmid">17185413</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>AT</given-names></name><name><surname>Habib</surname><given-names>FK</given-names></name><name><surname>Maitland</surname><given-names>NJ</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name></person-group>
<article-title>Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression</article-title>. <source>J Cell Sci</source> (<year>2001</year>) <volume>114</volume>(<issue>Pt 21</issue>):<fpage>3865</fpage>&#x02013;<lpage>72</lpage><pub-id pub-id-type="pmid">11719553</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>GD</given-names></name><name><surname>Robson</surname><given-names>CN</given-names></name><name><surname>Lang</surname><given-names>SH</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name><name><surname>Maitland</surname><given-names>NJ</given-names></name><name><surname>Collins</surname><given-names>AT</given-names></name></person-group>
<article-title>CD133, a novel marker for human prostatic epithelial stem cells</article-title>. <source>J Cell Sci</source> (<year>2004</year>) <volume>117</volume>(<issue>Pt 16</issue>):<fpage>3539</fpage>&#x02013;<lpage>45</lpage><pub-id pub-id-type="doi">10.1242/jcs.01222</pub-id><pub-id pub-id-type="pmid">15226377</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Kuipers</surname><given-names>J</given-names></name><name><surname>Kujala</surname><given-names>P</given-names></name><name><surname>van den Born</surname><given-names>M</given-names></name><name><surname>Cozijnsen</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Identification of stem cells in small intestine and colon by marker gene Lgr5</article-title>. <source>Nature</source> (<year>2007</year>) <volume>449</volume>(<issue>7165</issue>):<fpage>1003</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature06196</pub-id><pub-id pub-id-type="pmid">17934449</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winton</surname><given-names>DJ</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name></person-group>
<article-title>Stem-cell organization in mouse small intestine</article-title>. <source>Proc Biol Sci</source> (<year>1990</year>) <volume>241</volume>(<issue>1300</issue>):<fpage>13</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1098/rspb.1990.0059</pub-id><pub-id pub-id-type="pmid">1978330</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanpain</surname><given-names>C</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group>
<article-title>Epidermal homeostasis: a balancing act of stem cells in the skin</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2009</year>) <volume>10</volume>(<issue>3</issue>):<fpage>207</fpage>&#x02013;<lpage>17</lpage><pub-id pub-id-type="doi">10.1038/nrm2636</pub-id><pub-id pub-id-type="pmid">19209183</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group>
<article-title>Stem cells, cancer, and cancer stem cells</article-title>. <source>Nature</source> (<year>2001</year>) <volume>414</volume>(<issue>6859</issue>):<fpage>105</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1038/35102167</pub-id><pub-id pub-id-type="pmid">11689955</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orkin</surname><given-names>SH</given-names></name></person-group>
<article-title>Diversification of haematopoietic stem cells to specific lineages</article-title>. <source>Nat Rev Genet</source> (<year>2000</year>) <volume>1</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="doi">10.1038/35049577</pub-id><pub-id pub-id-type="pmid">11262875</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passegue</surname><given-names>E</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Giuriato</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>WC</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group>
<article-title>Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>202</volume>(<issue>11</issue>):<fpage>1599</fpage>&#x02013;<lpage>611</lpage><pub-id pub-id-type="doi">10.1084/jem.20050967</pub-id><pub-id pub-id-type="pmid">16330818</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group>
<article-title>Stem cells: units of development, units of regeneration, and units in evolution</article-title>. <source>Cell</source> (<year>2000</year>) <volume>100</volume>(<issue>1</issue>):<fpage>157</fpage>&#x02013;<lpage>68</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81692-X</pub-id><pub-id pub-id-type="pmid">10647940</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Laurenti</surname><given-names>E</given-names></name><name><surname>Oser</surname><given-names>G</given-names></name><name><surname>van der Wath</surname><given-names>RC</given-names></name><name><surname>Blanco-Bose</surname><given-names>W</given-names></name><name><surname>Jaworski</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair</article-title>. <source>Cell</source> (<year>2008</year>) <volume>135</volume>(<issue>6</issue>):<fpage>1118</fpage>&#x02013;<lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.10.048</pub-id><pub-id pub-id-type="pmid">19062086</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowell</surname><given-names>PC</given-names></name></person-group>
<article-title>The clonal evolution of tumor cell populations</article-title>. <source>Science</source> (<year>1976</year>) <volume>194</volume>(<issue>4260</issue>):<fpage>23</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.959840</pub-id><pub-id pub-id-type="pmid">959840</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>DJ</given-names></name></person-group>
<article-title>The two &#x0201c;hit&#x0201d; and multiple &#x0201c;hit&#x0201d; theories of carcinogenesis</article-title>. <source>Br J Cancer</source> (<year>1969</year>) <volume>23</volume>(<issue>2</issue>):<fpage>313</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="doi">10.1038/bjc.1969.41</pub-id><pub-id pub-id-type="pmid">5788039</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordling</surname><given-names>CO</given-names></name></person-group>
<article-title>A new theory on cancer-inducing mechanism</article-title>. <source>Br J Cancer</source> (<year>1953</year>) <volume>7</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>72</lpage><pub-id pub-id-type="doi">10.1038/bjc.1953.8</pub-id><pub-id pub-id-type="pmid">13051507</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinsmith</surname><given-names>LJ</given-names></name><name><surname>Pierce</surname><given-names>GB</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Multipotentiality of single embryonal carcinoma cells</article-title>. <source>Cancer Res</source> (<year>1964</year>) <volume>24</volume>:<fpage>1544</fpage>&#x02013;<lpage>51</lpage><pub-id pub-id-type="pmid">14234000</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Schuetz</surname><given-names>JD</given-names></name><name><surname>Bunting</surname><given-names>KD</given-names></name><name><surname>Colapietro</surname><given-names>AM</given-names></name><name><surname>Sampath</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype</article-title>. <source>Nat Med</source> (<year>2001</year>) <volume>7</volume>(<issue>9</issue>):<fpage>1028</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nm0901-1028</pub-id><pub-id pub-id-type="pmid">11533706</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlush</surname><given-names>LI</given-names></name><name><surname>Chapal-Ilani</surname><given-names>N</given-names></name><name><surname>Adar</surname><given-names>R</given-names></name><name><surname>Pery</surname><given-names>N</given-names></name><name><surname>Maruvka</surname><given-names>Y</given-names></name><name><surname>Spiro</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and miscrosatellite instability</article-title>. <source>Blood</source> (<year>2012</year>) <bold>120</bold>(<issue>3</issue>):<fpage>603</fpage>&#x02013;<lpage>12</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-10-388629</pub-id><pub-id pub-id-type="pmid">22645183</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>PM</given-names></name><name><surname>Roninson</surname><given-names>IB</given-names></name></person-group>
<article-title>Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells</article-title>. <source>Cell</source> (<year>1991</year>) <volume>66</volume>(<issue>1</issue>):<fpage>85</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90141-K</pub-id><pub-id pub-id-type="pmid">1712673</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooreman</surname><given-names>NG</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group>
<article-title>Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging</article-title>. <source>J R Soc Interface</source> (<year>2010</year>) <volume>7</volume>(<issue>Suppl 6</issue>):<fpage>S753</fpage>&#x02013;<lpage>63</lpage><pub-id pub-id-type="doi">10.1098/rsif.2010.0353.focus</pub-id><pub-id pub-id-type="pmid">20880852</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Neaves</surname><given-names>WB</given-names></name></person-group>
<article-title>Normal stem cells and cancer stem cells: the niche matters</article-title>. <source>Cancer Res</source> (<year>2006</year>) <volume>66</volume>(<issue>9</issue>):<fpage>4553</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3986</pub-id><pub-id pub-id-type="pmid">16651403</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>E</given-names></name><name><surname>Vaillant</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Forrest</surname><given-names>NC</given-names></name><name><surname>Pal</surname><given-names>B</given-names></name><name><surname>Hart</surname><given-names>AH</given-names></name><etal/></person-group>
<article-title>Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers</article-title>. <source>Nat Med</source> (<year>2009</year>) <volume>15</volume>(<issue>8</issue>):<fpage>907</fpage>&#x02013;<lpage>13</lpage><pub-id pub-id-type="doi">10.1038/nm.2000</pub-id><pub-id pub-id-type="pmid">19648928</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molyneux</surname><given-names>G</given-names></name><name><surname>Geyer</surname><given-names>FC</given-names></name><name><surname>Magnay</surname><given-names>FA</given-names></name><name><surname>McCarthy</surname><given-names>A</given-names></name><name><surname>Kendrick</surname><given-names>H</given-names></name><name><surname>Natrajan</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells</article-title>. <source>Cell Stem Cell</source> (<year>2010</year>) <volume>7</volume>(<issue>3</issue>):<fpage>403</fpage>&#x02013;<lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.07.010</pub-id><pub-id pub-id-type="pmid">20804975</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>AS</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Garraway</surname><given-names>IP</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name></person-group>
<article-title>Identification of a cell of origin for human prostate cancer</article-title>. <source>Science</source> (<year>2010</year>) <volume>329</volume>(<issue>5991</issue>):<fpage>568</fpage>&#x02013;<lpage>71</lpage><pub-id pub-id-type="doi">10.1126/science.1189992</pub-id><pub-id pub-id-type="pmid">20671189</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name><name><surname>Dirks</surname><given-names>PB</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Jamieson</surname><given-names>CH</given-names></name><name><surname>Jones</surname><given-names>DL</given-names></name><etal/></person-group>
<article-title>Cancer stem cells &#x02013; perspectives on current status and future directions: AACR Workshop on cancer stem cells</article-title>. <source>Cancer Res</source> (<year>2006</year>) <volume>66</volume>(<issue>19</issue>):<fpage>9339</fpage>&#x02013;<lpage>44</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3126</pub-id><pub-id pub-id-type="pmid">16990346</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group>
<article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title>. <source>Cell</source> (<year>2006</year>) <volume>126</volume>(<issue>4</issue>):<fpage>663</fpage>&#x02013;<lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.07.024</pub-id><pub-id pub-id-type="pmid">16904174</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaffer</surname><given-names>CL</given-names></name><name><surname>Brueckmann</surname><given-names>I</given-names></name><name><surname>Scheel</surname><given-names>C</given-names></name><name><surname>Kaestli</surname><given-names>AJ</given-names></name><name><surname>Wiggins</surname><given-names>PA</given-names></name><name><surname>Rodrigues</surname><given-names>LO</given-names></name><etal/></person-group>
<article-title>Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2011</year>) <volume>108</volume>(<issue>19</issue>):<fpage>7950</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.1102454108</pub-id><pub-id pub-id-type="pmid">21498687</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santisteban</surname><given-names>M</given-names></name><name><surname>Reiman</surname><given-names>JM</given-names></name><name><surname>Asiedu</surname><given-names>MK</given-names></name><name><surname>Behrens</surname><given-names>MD</given-names></name><name><surname>Nassar</surname><given-names>A</given-names></name><name><surname>Kalli</surname><given-names>KR</given-names></name><etal/></person-group>
<article-title>Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>7</issue>):<fpage>2887</fpage>&#x02013;<lpage>95</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3343</pub-id><pub-id pub-id-type="pmid">19276366</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>A</given-names></name><name><surname>Legendre</surname><given-names>P</given-names></name><name><surname>Prevot</surname><given-names>V</given-names></name><name><surname>Allet</surname><given-names>C</given-names></name><name><surname>Romao</surname><given-names>L</given-names></name><name><surname>Studler</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Transforming growth factor alpha promotes sequential conversion of mature astrocytes into neural progenitors and stem cells</article-title>. <source>Oncogene</source> (<year>2007</year>) <volume>26</volume>(<issue>19</issue>):<fpage>2695</fpage>&#x02013;<lpage>706</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210071</pub-id><pub-id pub-id-type="pmid">17057735</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>PB</given-names></name><name><surname>Fillmore</surname><given-names>CM</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Shapira</surname><given-names>SD</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Kuperwasser</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells</article-title>. <source>Cell</source> (<year>2011</year>) <volume>146</volume>(<issue>4</issue>):<fpage>633</fpage>&#x02013;<lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.07.026</pub-id><pub-id pub-id-type="pmid">21854987</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landsberg</surname><given-names>J</given-names></name><name><surname>Kohlmeyer</surname><given-names>J</given-names></name><name><surname>Renn</surname><given-names>M</given-names></name><name><surname>Bald</surname><given-names>T</given-names></name><name><surname>Rogava</surname><given-names>M</given-names></name><name><surname>Cron</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation</article-title>. <source>Nature</source> (<year>2012</year>) <volume>490</volume>(<issue>7420</issue>):<fpage>412</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature11538</pub-id><pub-id pub-id-type="pmid">23051752</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantozzi</surname><given-names>A</given-names></name><name><surname>Gruber</surname><given-names>DC</given-names></name><name><surname>Pisarsky</surname><given-names>L</given-names></name><name><surname>Heck</surname><given-names>C</given-names></name><name><surname>Kunita</surname><given-names>A</given-names></name><name><surname>Yilmaz</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation</article-title>. <source>Cancer Res</source> (<year>2014</year>) <volume>74</volume>(<issue>5</issue>):<fpage>1566</fpage>&#x02013;<lpage>75</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1641</pub-id><pub-id pub-id-type="pmid">24413534</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group>
<article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2014</year>) <volume>15</volume>(<issue>3</issue>):<fpage>178</fpage>&#x02013;<lpage>96</lpage><pub-id pub-id-type="doi">10.1038/nrm3758</pub-id><pub-id pub-id-type="pmid">24556840</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group>
<article-title>Epithelial plasticity: a common theme in embryonic and cancer cells</article-title>. <source>Science</source> (<year>2013</year>) <volume>342</volume>(<issue>6159</issue>):<fpage>1234850</fpage><pub-id pub-id-type="doi">10.1126/science.1234850</pub-id><pub-id pub-id-type="pmid">24202173</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>TK</given-names></name><name><surname>Leishear</surname><given-names>K</given-names></name><name><surname>Finko</surname><given-names>R</given-names></name><name><surname>Kulp</surname><given-names>AN</given-names></name><name><surname>Hotz</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>A tumorigenic subpopulation with stem cell properties in melanomas</article-title>. <source>Cancer Res</source> (<year>2005</year>) <volume>65</volume>(<issue>20</issue>):<fpage>9328</fpage>&#x02013;<lpage>37</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1343</pub-id><pub-id pub-id-type="pmid">16230395</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monzani</surname><given-names>E</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Galmozzi</surname><given-names>E</given-names></name><name><surname>Corsini</surname><given-names>E</given-names></name><name><surname>Benetti</surname><given-names>A</given-names></name><name><surname>Cavazzin</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential</article-title>. <source>Eur J Cancer</source> (<year>2007</year>) <volume>43</volume>(<issue>5</issue>):<fpage>935</fpage>&#x02013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2007.01.017</pub-id><pub-id pub-id-type="pmid">17320377</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshet</surname><given-names>GI</given-names></name><name><surname>Goldstein</surname><given-names>I</given-names></name><name><surname>Itzhaki</surname><given-names>O</given-names></name><name><surname>Cesarkas</surname><given-names>K</given-names></name><name><surname>Shenhav</surname><given-names>L</given-names></name><name><surname>Yakirevitch</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>MDR1 expression identifies human melanoma stem cells</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2008</year>) <volume>368</volume>(<issue>4</issue>):<fpage>930</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.02.022</pub-id><pub-id pub-id-type="pmid">18279661</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boiko</surname><given-names>AD</given-names></name><name><surname>Razorenova</surname><given-names>OV</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Swetter</surname><given-names>SM</given-names></name><name><surname>Johnson</surname><given-names>DL</given-names></name><name><surname>Ly</surname><given-names>DP</given-names></name><etal/></person-group>
<article-title>Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271</article-title>. <source>Nature</source> (<year>2010</year>) <volume>466</volume>(<issue>7302</issue>):<fpage>133</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature09161</pub-id><pub-id pub-id-type="pmid">20596026</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>PB</given-names></name><name><surname>Chaffer</surname><given-names>CL</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group>
<article-title>Cancer stem cells: mirage or reality?</article-title>
<source>Nat Med</source> (<year>2009</year>) <volume>15</volume>(<issue>9</issue>):<fpage>1010</fpage>&#x02013;<lpage>2</lpage><pub-id pub-id-type="doi">10.1038/nm0909-1010</pub-id><pub-id pub-id-type="pmid">19734877</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eaves</surname><given-names>CJ</given-names></name></person-group>
<article-title>Cancer stem cells: here, there, everywhere?</article-title>
<source>Nature</source> (<year>2008</year>) <volume>456</volume>(<issue>7222</issue>):<fpage>581</fpage>&#x02013;<lpage>2</lpage><pub-id pub-id-type="doi">10.1038/456581a</pub-id><pub-id pub-id-type="pmid">19052611</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passegue</surname><given-names>E</given-names></name><name><surname>Rafii</surname><given-names>S</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group>
<article-title>Cancer stem cells are everywhere</article-title>. <source>Nat Med</source> (<year>2009</year>) <volume>15</volume>(<issue>1</issue>):<fpage>23</fpage><pub-id pub-id-type="doi">10.1038/nm0109-23</pub-id><pub-id pub-id-type="pmid">19129778</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>E</given-names></name><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Sabel</surname><given-names>MS</given-names></name><name><surname>Fullen</surname><given-names>DR</given-names></name><name><surname>Johnson</surname><given-names>TM</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group>
<article-title>Efficient tumour formation by single human melanoma cells</article-title>. <source>Nature</source> (<year>2008</year>) <volume>456</volume>(<issue>7222</issue>):<fpage>593</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature07567</pub-id><pub-id pub-id-type="pmid">19052619</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>E</given-names></name><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>HR</given-names></name><name><surname>Fullen</surname><given-names>DR</given-names></name><name><surname>Sabel</surname><given-names>MS</given-names></name><name><surname>Johnson</surname><given-names>TM</given-names></name><etal/></person-group>
<article-title>Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized</article-title>. <source>Cancer Cell</source> (<year>2010</year>) <volume>18</volume>(<issue>5</issue>):<fpage>510</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.10.012</pub-id><pub-id pub-id-type="pmid">21075313</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdullah</surname><given-names>LN</given-names></name><name><surname>Chow</surname><given-names>EK</given-names></name></person-group>
<article-title>Mechanisms of chemoresistance in cancer stem cells</article-title>. <source>Clin Transl Med</source> (<year>2013</year>) <volume>2</volume>(<issue>1</issue>):<fpage>3</fpage><pub-id pub-id-type="doi">10.1186/2001-1326-2-3</pub-id><pub-id pub-id-type="pmid">23369605</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Cozzi</surname><given-names>P</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Graham</surname><given-names>P</given-names></name><name><surname>Kearsley</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Cancer stem cells in prostate cancer chemoresistance</article-title>. <source>Curr Cancer Drug Targets</source> (<year>2014</year>) <volume>14</volume>(<issue>3</issue>):<fpage>225</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.2174/1568009614666140328152459</pub-id><pub-id pub-id-type="pmid">24720286</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamai</surname><given-names>A</given-names></name><name><surname>Meslin</surname><given-names>F</given-names></name><name><surname>Benlalam</surname><given-names>H</given-names></name><name><surname>Jalil</surname><given-names>A</given-names></name><name><surname>Mehrpour</surname><given-names>M</given-names></name><name><surname>Faure</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway</article-title>. <source>Cancer Res</source> (<year>2008</year>) <volume>68</volume>(<issue>23</issue>):<fpage>9854</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0719</pub-id><pub-id pub-id-type="pmid">19047166</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knuefermann</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells</article-title>. <source>Oncogene</source> (<year>2003</year>) <volume>22</volume>(<issue>21</issue>):<fpage>3205</fpage>&#x02013;<lpage>12</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206394</pub-id><pub-id pub-id-type="pmid">12761490</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seliger</surname><given-names>B</given-names></name><name><surname>Kiessling</surname><given-names>R</given-names></name></person-group>
<article-title>The two sides of HER2/neu: immune escape versus surveillance</article-title>. <source>Trends Mol Med</source> (<year>2013</year>) <volume>19</volume>(<issue>11</issue>):<fpage>677</fpage>&#x02013;<lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2013.08.003</pub-id><pub-id pub-id-type="pmid">24035606</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mimura</surname><given-names>K</given-names></name><name><surname>Shiraishi</surname><given-names>K</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Izawa</surname><given-names>S</given-names></name><name><surname>Kua</surname><given-names>LF</given-names></name><name><surname>So</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>(<issue>12</issue>):<fpage>6261</fpage>&#x02013;<lpage>72</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301597</pub-id><pub-id pub-id-type="pmid">24244023</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ithimakin</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>KC</given-names></name><name><surname>Malik</surname><given-names>F</given-names></name><name><surname>Zen</surname><given-names>Q</given-names></name><name><surname>Dawsey</surname><given-names>SJ</given-names></name><name><surname>Bersano-Begey</surname><given-names>TF</given-names></name><etal/></person-group>
<article-title>HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab</article-title>. <source>Cancer Res</source> (<year>2013</year>) <volume>73</volume>(<issue>5</issue>):<fpage>1635</fpage>&#x02013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3349</pub-id><pub-id pub-id-type="pmid">23442322</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schatton</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>MH</given-names></name></person-group>
<article-title>Antitumor immunity and cancer stem cells</article-title>. <source>Ann N Y Acad Sci</source> (<year>2009</year>) <volume>1176</volume>:<fpage>154</fpage>&#x02013;<lpage>69</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04568.x</pub-id><pub-id pub-id-type="pmid">19796244</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reim</surname><given-names>F</given-names></name><name><surname>Dombrowski</surname><given-names>Y</given-names></name><name><surname>Ritter</surname><given-names>C</given-names></name><name><surname>Buttmann</surname><given-names>M</given-names></name><name><surname>H&#x000e4;usler</surname><given-names>S</given-names></name><name><surname>Ossadnik</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>20</issue>):<fpage>8058</fpage>&#x02013;<lpage>66</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0834</pub-id><pub-id pub-id-type="pmid">19826050</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Tomaso</surname><given-names>T</given-names></name><name><surname>Mazzoleni</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Sovena</surname><given-names>G</given-names></name><name><surname>Clavenna</surname><given-names>D</given-names></name><name><surname>Franzin</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Immunobiological characterization of cancer stem cells isolated from glioblastoma patients</article-title>. <source>Clin Cancer Res</source> (<year>2010</year>) <volume>16</volume>(<issue>3</issue>):<fpage>800</fpage>&#x02013;<lpage>13</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-2730</pub-id><pub-id pub-id-type="pmid">20103663</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schatton</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>MH</given-names></name></person-group>
<article-title>Cancer stem cells and human malignant melanoma</article-title>. <source>Pigment Cell Melanoma Res</source> (<year>2008</year>) <volume>21</volume>(<issue>1</issue>):<fpage>39</fpage>&#x02013;<lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2007.00427.x</pub-id><pub-id pub-id-type="pmid">18353142</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shipitsin</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>LL</given-names></name><name><surname>Argani</surname><given-names>P</given-names></name><name><surname>Weremowicz</surname><given-names>S</given-names></name><name><surname>Bloushtain-Qimron</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Molecular definition of breast tumor heterogeneity</article-title>. <source>Cancer Cell</source> (<year>2007</year>) <volume>11</volume>(<issue>3</issue>):<fpage>259</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.01.013</pub-id><pub-id pub-id-type="pmid">17349583</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lottaz</surname><given-names>C</given-names></name><name><surname>Beier</surname><given-names>D</given-names></name><name><surname>Meyer</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Hermann</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Transcriptional profiles of CD133+ and CD133&#x02212; glioblastoma-derived cancer stem cell lines suggest different cells of origin</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>(<issue>5</issue>):<fpage>2030</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1707</pub-id><pub-id pub-id-type="pmid">20145155</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Alea</surname><given-names>MP</given-names></name><name><surname>Di Stefano</surname><given-names>AB</given-names></name><name><surname>Cammareri</surname><given-names>P</given-names></name><name><surname>Vermeulen</surname><given-names>L</given-names></name><name><surname>Iovino</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4</article-title>. <source>Cell Stem Cell</source> (<year>2007</year>) <volume>1</volume>(<issue>4</issue>):<fpage>389</fpage>&#x02013;<lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.08.001</pub-id><pub-id pub-id-type="pmid">18371377</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olver</surname><given-names>S</given-names></name><name><surname>Groves</surname><given-names>P</given-names></name><name><surname>Buttigieg</surname><given-names>K</given-names></name><name><surname>Morris</surname><given-names>ES</given-names></name><name><surname>Janas</surname><given-names>ML</given-names></name><name><surname>Kelso</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells</article-title>. <source>Cancer Res</source> (<year>2006</year>) <volume>66</volume>(<issue>1</issue>):<fpage>571</fpage>&#x02013;<lpage>80</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1362</pub-id><pub-id pub-id-type="pmid">16397274</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>BT</given-names></name><name><surname>Mistree</surname><given-names>T</given-names></name><name><surname>Hurt</surname><given-names>EM</given-names></name><name><surname>Kalathur</surname><given-names>M</given-names></name><name><surname>Farrar</surname><given-names>WL</given-names></name></person-group>
<article-title>Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2007</year>) <volume>364</volume>(<issue>4</issue>):<fpage>778</fpage>&#x02013;<lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.10.067</pub-id><pub-id pub-id-type="pmid">17964286</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>BT</given-names></name><name><surname>Farrar</surname><given-names>WL</given-names></name></person-group>
<article-title>Cancer stem cells, CD200 and immunoevasion</article-title>. <source>Trends Immunol</source> (<year>2008</year>) <volume>29</volume>(<issue>10</issue>):<fpage>464</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.it.2008.07.005</pub-id><pub-id pub-id-type="pmid">18775673</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kretz-Rommel</surname><given-names>A</given-names></name><name><surname>Qin</surname><given-names>F</given-names></name><name><surname>Dakappagari</surname><given-names>N</given-names></name><name><surname>Ravey</surname><given-names>EP</given-names></name><name><surname>McWhirter</surname><given-names>J</given-names></name><name><surname>Oltean</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>9</issue>):<fpage>5595</fpage>&#x02013;<lpage>605</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.9.5595</pub-id><pub-id pub-id-type="pmid">17442942</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maccalli</surname><given-names>C</given-names></name><name><surname>Volonte</surname><given-names>A</given-names></name><name><surname>Cimminiello</surname><given-names>C</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name></person-group>
<article-title>Immunology of cancer stem cells in solid tumours. A review</article-title>. <source>Eur J Cancer</source> (<year>2014</year>) <volume>50</volume>(<issue>3</issue>):<fpage>649</fpage>&#x02013;<lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.11.014</pub-id><pub-id pub-id-type="pmid">24333096</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drukker</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>G</given-names></name><name><surname>Urbach</surname><given-names>A</given-names></name><name><surname>Schuldiner</surname><given-names>M</given-names></name><name><surname>Markel</surname><given-names>G</given-names></name><name><surname>Itskovitz-Eldor</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Characterization of the expression of MHC proteins in human embryonic stem cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2002</year>) <volume>99</volume>(<issue>15</issue>):<fpage>9864</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.142298299</pub-id><pub-id pub-id-type="pmid">12114532</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favier</surname><given-names>B</given-names></name><name><surname>LeMaoult</surname><given-names>J</given-names></name><name><surname>Carosella</surname><given-names>ED</given-names></name></person-group>
<article-title>Functions of HLA-G in the immune system</article-title>. <source>Tissue Antigens</source> (<year>2007</year>) <volume>69</volume>(<issue>Suppl 1</issue>):<fpage>150</fpage>&#x02013;<lpage>2</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0039.2006.763_6.x</pub-id><pub-id pub-id-type="pmid">17445191</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verloes</surname><given-names>A</given-names></name><name><surname>Van de Velde</surname><given-names>H</given-names></name><name><surname>LeMaoult</surname><given-names>J</given-names></name><name><surname>Mateizel</surname><given-names>I</given-names></name><name><surname>Cauffman</surname><given-names>G</given-names></name><name><surname>Horn</surname><given-names>PA</given-names></name><etal/></person-group>
<article-title>HLA-G expression in human embryonic stem cells and preimplantation embryos</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>(<issue>4</issue>):<fpage>2663</fpage>&#x02013;<lpage>71</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001081</pub-id><pub-id pub-id-type="pmid">21248264</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasef</surname><given-names>A</given-names></name><name><surname>Mathieu</surname><given-names>N</given-names></name><name><surname>Chapel</surname><given-names>A</given-names></name><name><surname>Frick</surname><given-names>J</given-names></name><name><surname>Francois</surname><given-names>S</given-names></name><name><surname>Mazurier</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G</article-title>. <source>Transplantation</source> (<year>2007</year>) <volume>84</volume>(<issue>2</issue>):<fpage>231</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1097/01.tp.0000267918.07906.08</pub-id><pub-id pub-id-type="pmid">17667815</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroczek</surname><given-names>RA</given-names></name><name><surname>Mages</surname><given-names>HW</given-names></name><name><surname>Hutloff</surname><given-names>A</given-names></name></person-group>
<article-title>Emerging paradigms of T-cell co-stimulation</article-title>. <source>Curr Opin Immunol</source> (<year>2004</year>) <volume>16</volume>(<issue>3</issue>):<fpage>321</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2004.03.002</pub-id><pub-id pub-id-type="pmid">15134781</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krampera</surname><given-names>M</given-names></name><name><surname>Cosmi</surname><given-names>L</given-names></name><name><surname>Angeli</surname><given-names>R</given-names></name><name><surname>Pasini</surname><given-names>A</given-names></name><name><surname>Liotta</surname><given-names>F</given-names></name><name><surname>Andreini</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells</article-title>. <source>Stem Cells</source> (<year>2006</year>) <volume>24</volume>(<issue>2</issue>):<fpage>386</fpage>&#x02013;<lpage>98</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2005-0008</pub-id><pub-id pub-id-type="pmid">16123384</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Blanc</surname><given-names>K</given-names></name></person-group>
<article-title>Immunomodulatory effects of fetal and adult mesenchymal stem cells</article-title>. <source>Cytotherapy</source> (<year>2003</year>) <volume>5</volume>(<issue>6</issue>):<fpage>485</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1080/14653240310003611</pub-id><pub-id pub-id-type="pmid">14660044</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Blanc</surname><given-names>K</given-names></name><name><surname>Tammik</surname><given-names>C</given-names></name><name><surname>Rosendahl</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>E</given-names></name><name><surname>Ringden</surname><given-names>O</given-names></name></person-group>
<article-title>HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells</article-title>. <source>Exp Hematol</source> (<year>2003</year>) <volume>31</volume>(<issue>10</issue>):<fpage>890</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0301-472X(03)00110-3</pub-id><pub-id pub-id-type="pmid">14550804</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>Pittenger</surname><given-names>MF</given-names></name></person-group>
<article-title>Human mesenchymal stem cells modulate allogeneic immune cell responses</article-title>. <source>Blood</source> (<year>2005</year>) <volume>105</volume>(<issue>4</issue>):<fpage>1815</fpage>&#x02013;<lpage>22</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-04-1559</pub-id><pub-id pub-id-type="pmid">15494428</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>SG</given-names></name><name><surname>Padilla</surname><given-names>J</given-names></name><name><surname>Koumas</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Phipps</surname><given-names>RP</given-names></name></person-group>
<article-title>Prostaglandins as modulators of immunity</article-title>. <source>Trends Immunol</source> (<year>2002</year>) <volume>23</volume>(<issue>3</issue>):<fpage>144</fpage>&#x02013;<lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S1471-4906(01)02154-8</pub-id><pub-id pub-id-type="pmid">11864843</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meisel</surname><given-names>R</given-names></name><name><surname>Zibert</surname><given-names>A</given-names></name><name><surname>Laryea</surname><given-names>M</given-names></name><name><surname>Gobel</surname><given-names>U</given-names></name><name><surname>Daubener</surname><given-names>W</given-names></name><name><surname>Dilloo</surname><given-names>D</given-names></name></person-group>
<article-title>Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation</article-title>. <source>Blood</source> (<year>2004</year>) <volume>103</volume>(<issue>12</issue>):<fpage>4619</fpage>&#x02013;<lpage>21</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-11-3909</pub-id><pub-id pub-id-type="pmid">15001472</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Lennon</surname><given-names>DP</given-names></name><name><surname>Caplan</surname><given-names>AI</given-names></name><name><surname>Dechant</surname><given-names>A</given-names></name><name><surname>Hecker</surname><given-names>J</given-names></name><name><surname>Kranso</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models</article-title>. <source>Nat Neurosci</source> (<year>2012</year>) <volume>15</volume>(<issue>6</issue>):<fpage>862</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nn.3109</pub-id><pub-id pub-id-type="pmid">22610068</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benkhoucha</surname><given-names>M</given-names></name><name><surname>Santiago-Raber</surname><given-names>ML</given-names></name><name><surname>Schneiter</surname><given-names>G</given-names></name><name><surname>Chofflon</surname><given-names>M</given-names></name><name><surname>Funakoshi</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2010</year>) <volume>107</volume>(<issue>14</issue>):<fpage>6424</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912437107</pub-id><pub-id pub-id-type="pmid">20332205</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krampera</surname><given-names>M</given-names></name><name><surname>Glennie</surname><given-names>S</given-names></name><name><surname>Dyson</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Laylor</surname><given-names>R</given-names></name><name><surname>Simpson</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide</article-title>. <source>Blood</source> (<year>2003</year>) <volume>101</volume>(<issue>9</issue>):<fpage>3722</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-07-2104</pub-id><pub-id pub-id-type="pmid">12506037</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitra</surname><given-names>B</given-names></name><name><surname>Szekely</surname><given-names>E</given-names></name><name><surname>Gjini</surname><given-names>K</given-names></name><name><surname>Laughlin</surname><given-names>MJ</given-names></name><name><surname>Dennis</surname><given-names>J</given-names></name><name><surname>Haynesworth</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation</article-title>. <source>Bone Marrow Transplant</source> (<year>2004</year>) <volume>33</volume>(<issue>6</issue>):<fpage>597</fpage>&#x02013;<lpage>604</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1704400</pub-id><pub-id pub-id-type="pmid">14716336</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>WT</given-names></name><name><surname>Pendleton</surname><given-names>JD</given-names></name><name><surname>Beyer</surname><given-names>WM</given-names></name><name><surname>Egalka</surname><given-names>MC</given-names></name><name><surname>Guinan</surname><given-names>EC</given-names></name></person-group>
<article-title>Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation</article-title>. <source>Transplantation</source> (<year>2003</year>) <volume>75</volume>(<issue>3</issue>):<fpage>389</fpage>&#x02013;<lpage>97</lpage><pub-id pub-id-type="doi">10.1097/01.TP.0000045055.63901.A9</pub-id><pub-id pub-id-type="pmid">12589164</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>JW</given-names></name><name><surname>Liu</surname><given-names>XZ</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Mickey</surname><given-names>SK</given-names></name><name><surname>Turetsky</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord</article-title>. <source>Nat Med</source> (<year>1999</year>) <volume>5</volume>(<issue>12</issue>):<fpage>1410</fpage>&#x02013;<lpage>2</lpage><pub-id pub-id-type="doi">10.1038/70986</pub-id><pub-id pub-id-type="pmid">10581084</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>C</given-names></name><name><surname>Hagege</surname><given-names>AA</given-names></name><name><surname>Agbulut</surname><given-names>O</given-names></name><name><surname>Barro</surname><given-names>M</given-names></name><name><surname>Morichetti</surname><given-names>MC</given-names></name><name><surname>Brasselet</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study</article-title>. <source>Lancet</source> (<year>2005</year>) <volume>366</volume>(<issue>9490</issue>):<fpage>1005</fpage>&#x02013;<lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67380-1</pub-id><pub-id pub-id-type="pmid">16168783</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemeyer</surname><given-names>P</given-names></name><name><surname>Schonberger</surname><given-names>TS</given-names></name><name><surname>Hahn</surname><given-names>J</given-names></name><name><surname>Kasten</surname><given-names>P</given-names></name><name><surname>Fellenberg</surname><given-names>J</given-names></name><name><surname>Suedkamp</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Xenogenic transplantation of human mesenchymal stem cells in a critical size defect of the sheep tibia for bone regeneration</article-title>. <source>Tissue Eng Part A</source> (<year>2010</year>) <volume>16</volume>(<issue>1</issue>):<fpage>33</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="doi">10.1089/ten.TEA.2009.0190</pub-id><pub-id pub-id-type="pmid">19604039</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Blanc</surname><given-names>K</given-names></name><name><surname>Frassoni</surname><given-names>F</given-names></name><name><surname>Ball</surname><given-names>L</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Roelofs</surname><given-names>H</given-names></name><name><surname>Lewis</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study</article-title>. <source>Lancet</source> (<year>2008</year>) <volume>371</volume>(<issue>9624</issue>):<fpage>1579</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60690-X</pub-id><pub-id pub-id-type="pmid">18468541</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roemeling-van Rhijn</surname><given-names>M</given-names></name><name><surname>Weimar</surname><given-names>W</given-names></name><name><surname>Hoogduijn</surname><given-names>MJ</given-names></name></person-group>
<article-title>Mesenchymal stem cells: application for solid-organ transplantation</article-title>. <source>Curr Opin Organ Transplant</source> (<year>2012</year>) <volume>17</volume>(<issue>1</issue>):<fpage>55</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="doi">10.1097/MOT.0b013e32834ee676</pub-id><pub-id pub-id-type="pmid">22186092</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shultz</surname><given-names>LD</given-names></name><name><surname>Lyons</surname><given-names>BL</given-names></name><name><surname>Burzenski</surname><given-names>LM</given-names></name><name><surname>Gott</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chaleff</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>174</volume>(<issue>10</issue>):<fpage>6477</fpage>&#x02013;<lpage>89</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.10.6477</pub-id><pub-id pub-id-type="pmid">15879151</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapidot</surname><given-names>T</given-names></name><name><surname>Sirard</surname><given-names>C</given-names></name><name><surname>Vormoor</surname><given-names>J</given-names></name><name><surname>Murdoch</surname><given-names>B</given-names></name><name><surname>Hoang</surname><given-names>T</given-names></name><name><surname>Caceres-Cortes</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</article-title>. <source>Nature</source> (<year>1994</year>) <volume>367</volume>(<issue>6464</issue>):<fpage>645</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/367645a0</pub-id><pub-id pub-id-type="pmid">7509044</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hajj</surname><given-names>M</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Benito-Hernandez</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name></person-group>
<article-title>Prospective identification of tumorigenic breast cancer cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2003</year>) <volume>100</volume>(<issue>7</issue>):<fpage>3983</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1073/pnas.0530291100</pub-id><pub-id pub-id-type="pmid">12629218</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>ID</given-names></name><name><surname>Squire</surname><given-names>JA</given-names></name><name><surname>Bayani</surname><given-names>J</given-names></name><name><surname>Hide</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Identification of human brain tumour initiating cells</article-title>. <source>Nature</source> (<year>2004</year>) <volume>432</volume>(<issue>7015</issue>):<fpage>396</fpage>&#x02013;<lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature03128</pub-id><pub-id pub-id-type="pmid">15549107</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>PN</given-names></name><name><surname>Dakic</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>JM</given-names></name><name><surname>Nutt</surname><given-names>SL</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name></person-group>
<article-title>Tumor growth need not be driven by rare cancer stem cells</article-title>. <source>Science</source> (<year>2007</year>) <volume>317</volume>(<issue>5836</issue>):<fpage>337</fpage><pub-id pub-id-type="doi">10.1126/science.1142596</pub-id><pub-id pub-id-type="pmid">17641192</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>JA</given-names></name><name><surname>Kaplan</surname><given-names>CD</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Markowitz</surname><given-names>D</given-names></name><name><surname>Xiang</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Characterization of stem cell-like cancer cells in immune-competent mice</article-title>. <source>Blood</source> (<year>2006</year>) <volume>108</volume>(<issue>12</issue>):<fpage>3906</fpage>&#x02013;<lpage>12</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-05-024687</pub-id><pub-id pub-id-type="pmid">16912222</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Bruce</surname><given-names>AT</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group>
<article-title>Cancer immunoediting: from immunosurveillance to tumor escape</article-title>. <source>Nat Immunol</source> (<year>2002</year>) <volume>3</volume>(<issue>11</issue>):<fpage>991</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/ni1102-991</pub-id><pub-id pub-id-type="pmid">12407406</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguirre-Ghiso</surname><given-names>JA</given-names></name></person-group>
<article-title>Models, mechanisms and clinical evidence for cancer dormancy</article-title>. <source>Nat Rev Cancer</source> (<year>2007</year>) <volume>7</volume>(<issue>11</issue>):<fpage>834</fpage>&#x02013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1038/nrc2256</pub-id><pub-id pub-id-type="pmid">17957189</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name></person-group>
<article-title>Stem cell niche: structure and function</article-title>. <source>Annu Rev Cell Dev Biol</source> (<year>2005</year>) <volume>21</volume>:<fpage>605</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.21.012704.131525</pub-id><pub-id pub-id-type="pmid">16212509</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlush</surname><given-names>LI</given-names></name><name><surname>Zandi</surname><given-names>S</given-names></name><name><surname>Mitchell</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Brandwein</surname><given-names>JM</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia</article-title>. <source>Nature</source> (<year>2014</year>) <volume>506</volume>(<issue>7488</issue>):<fpage>328</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nature13038</pub-id><pub-id pub-id-type="pmid">24522528</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>RN</given-names></name><name><surname>Riba</surname><given-names>RD</given-names></name><name><surname>Zacharoulis</surname><given-names>S</given-names></name><name><surname>Bramley</surname><given-names>AH</given-names></name><name><surname>Vincent</surname><given-names>L</given-names></name><name><surname>Costa</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche</article-title>. <source>Nature</source> (<year>2005</year>) <volume>438</volume>(<issue>7069</issue>):<fpage>820</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature04186</pub-id><pub-id pub-id-type="pmid">16341007</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sceneay</surname><given-names>J</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Moller</surname><given-names>A</given-names></name></person-group>
<article-title>The pre-metastatic niche: finding common ground</article-title>. <source>Cancer Metastasis Rev</source> (<year>2013</year>) <volume>32</volume>(<issue>3&#x02013;4</issue>):<fpage>449</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s10555-013-9420-1</pub-id><pub-id pub-id-type="pmid">23636348</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehling</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>P</given-names></name><name><surname>Mittelbronn</surname><given-names>M</given-names></name><name><surname>Meyermann</surname><given-names>R</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?</article-title>
<source>Acta Neuropathol</source> (<year>2007</year>) <volume>114</volume>(<issue>2</issue>):<fpage>111</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0231-8</pub-id><pub-id pub-id-type="pmid">17541610</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>BK</given-names></name><name><surname>Yim</surname><given-names>D</given-names></name><name><surname>Chow</surname><given-names>IT</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Mann</surname><given-names>HH</given-names></name><etal/></person-group>
<article-title>Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands</article-title>. <source>Nature</source> (<year>2007</year>) <volume>447</volume>(<issue>7143</issue>):<fpage>482</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature05768</pub-id><pub-id pub-id-type="pmid">17495932</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleason</surname><given-names>DF</given-names></name><name><surname>Mellinger</surname><given-names>GT</given-names></name></person-group>
<article-title>Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging</article-title>. <source>J Urol</source> (<year>1974</year>) <volume>111</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="pmid">4813554</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>Risueno</surname><given-names>RM</given-names></name><name><surname>Salati</surname><given-names>S</given-names></name><name><surname>Guezguez</surname><given-names>B</given-names></name><name><surname>Bhatia</surname><given-names>M</given-names></name></person-group>
<article-title>Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects</article-title>. <source>Curr Opin Hematol</source> (<year>2008</year>) <volume>15</volume>(<issue>4</issue>):<fpage>319</fpage>&#x02013;<lpage>25</lpage><pub-id pub-id-type="doi">10.1097/MOH.0b013e328303b9df</pub-id><pub-id pub-id-type="pmid">18536569</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takebe</surname><given-names>N</given-names></name><name><surname>Harris</surname><given-names>PJ</given-names></name><name><surname>Warren</surname><given-names>RQ</given-names></name><name><surname>Ivy</surname><given-names>SP</given-names></name></person-group>
<article-title>Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways</article-title>. <source>Nat Rev Clin Oncol</source> (<year>2011</year>) <volume>8</volume>(<issue>2</issue>):<fpage>97</fpage>&#x02013;<lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2010.196</pub-id><pub-id pub-id-type="pmid">21151206</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zardawi</surname><given-names>SJ</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>SA</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name></person-group>
<article-title>Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer</article-title>. <source>Histol Histopathol</source> (<year>2009</year>) <volume>24</volume>(<issue>3</issue>):<fpage>385</fpage>&#x02013;<lpage>98</lpage><pub-id pub-id-type="pmid">19130408</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taipale</surname><given-names>J</given-names></name><name><surname>Beachy</surname><given-names>PA</given-names></name></person-group>
<article-title>The Hedgehog and Wnt signalling pathways in cancer</article-title>. <source>Nature</source> (<year>2001</year>) <volume>411</volume>(<issue>6835</issue>):<fpage>349</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1038/35077219</pub-id><pub-id pub-id-type="pmid">11357142</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Bohin</surname><given-names>N</given-names></name><name><surname>Wen</surname><given-names>T</given-names></name><name><surname>Ng</surname><given-names>V</given-names></name><name><surname>Magee</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness</article-title>. <source>Nature</source> (<year>2013</year>) <volume>504</volume>(<issue>7478</issue>):<fpage>143</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature12830</pub-id><pub-id pub-id-type="pmid">24284627</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Kapoor</surname><given-names>GS</given-names></name><name><surname>Rohle</surname><given-names>D</given-names></name><name><surname>Turcan</surname><given-names>S</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>IDH mutation impairs histone demethylation and results in a block to cell differentiation</article-title>. <source>Nature</source> (<year>2012</year>) <volume>483</volume>(<issue>7390</issue>):<fpage>474</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature10860</pub-id><pub-id pub-id-type="pmid">22343901</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group>
<article-title>Disruption of differentiation in human cancer: AML shows the way</article-title>. <source>Nat Rev Cancer</source> (<year>2003</year>) <volume>3</volume>(<issue>2</issue>):<fpage>89</fpage>&#x02013;<lpage>101</lpage><pub-id pub-id-type="doi">10.1038/nrc989</pub-id><pub-id pub-id-type="pmid">12563308</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>TM</given-names></name><name><surname>McBride</surname><given-names>WH</given-names></name><name><surname>Pajonk</surname><given-names>F</given-names></name></person-group>
<article-title>The response of CD24(</article-title>&#x02212;<article-title>/low)/CD44+ breast cancer-initiating cells to radiation</article-title>. <source>J Natl Cancer Inst</source> (<year>2006</year>) <volume>98</volume>(<issue>24</issue>):<fpage>1777</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="doi">10.1093/jnci/djj495</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>D</given-names></name><name><surname>Rohrl</surname><given-names>S</given-names></name><name><surname>Pillai</surname><given-names>DR</given-names></name><name><surname>Schwarz</surname><given-names>S</given-names></name><name><surname>Kunz-Schughart</surname><given-names>LA</given-names></name><name><surname>Leukel</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Temozolomide preferentially depletes cancer stem cells in glioblastoma</article-title>. <source>Cancer Res</source> (<year>2008</year>) <volume>68</volume>(<issue>14</issue>):<fpage>5706</fpage>&#x02013;<lpage>15</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6878</pub-id><pub-id pub-id-type="pmid">18632623</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diessner</surname><given-names>J</given-names></name><name><surname>Bruttel</surname><given-names>V</given-names></name><name><surname>Stein</surname><given-names>R</given-names></name><name><surname>Horn</surname><given-names>E</given-names></name><name><surname>H&#x000e4;usler</surname><given-names>S</given-names></name><name><surname>Dietl</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Targeting of pre-existing and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)</article-title>. <source>Cell Death Dis</source> (<year>2014</year>) <volume>5</volume>:<fpage>e1149</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.115</pub-id><pub-id pub-id-type="pmid">24675467</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>BJ</given-names></name><name><surname>Schmidt</surname><given-names>CW</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>Reynolds</surname><given-names>BA</given-names></name><name><surname>Lopez</surname><given-names>JA</given-names></name></person-group>
<article-title>Breast cancer stem cells: implications for therapy of breast cancer</article-title>. <source>Breast Cancer Res</source> (<year>2008</year>) <volume>10</volume>(<issue>4</issue>):<fpage>210</fpage><pub-id pub-id-type="doi">10.1186/bcr2111</pub-id><pub-id pub-id-type="pmid">18671830</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>SY</given-names></name><name><surname>Hao</surname><given-names>YB</given-names></name><name><surname>Nan</surname><given-names>KJ</given-names></name><name><surname>Fan</surname><given-names>TL</given-names></name></person-group>
<article-title>Cancer stem cells niche: a target for novel cancer therapeutics</article-title>. <source>Cancer Treat Rev</source> (<year>2013</year>) <volume>39</volume>(<issue>3</issue>):<fpage>290</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2012.10.004</pub-id><pub-id pub-id-type="pmid">23219150</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borovski</surname><given-names>T</given-names></name><name><surname>De Sousa</surname><given-names>EMF</given-names></name><name><surname>Vermeulen</surname><given-names>L</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name></person-group>
<article-title>Cancer stem cell niche: the place to be</article-title>. <source>Cancer Res</source> (<year>2011</year>) <volume>71</volume>(<issue>3</issue>):<fpage>634</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3220</pub-id><pub-id pub-id-type="pmid">21266356</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malanchi</surname><given-names>I</given-names></name><name><surname>Santamaria-Martinez</surname><given-names>A</given-names></name><name><surname>Susanto</surname><given-names>E</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Lehr</surname><given-names>HA</given-names></name><name><surname>Delaloye</surname><given-names>JF</given-names></name><etal/></person-group>
<article-title>Interactions between cancer stem cells and their niche govern metastatic colonization</article-title>. <source>Nature</source> (<year>2012</year>) <volume>481</volume>(<issue>7379</issue>):<fpage>85</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature10694</pub-id><pub-id pub-id-type="pmid">22158103</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bowerman</surname><given-names>NA</given-names></name><name><surname>Schietinger</surname><given-names>A</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name><name><surname>Kranz</surname><given-names>DM</given-names></name><etal/></person-group>
<article-title>Equilibrium between host and cancer caused by effector T cells killing tumor stroma</article-title>. <source>Cancer Res</source> (<year>2008</year>) <volume>68</volume>(<issue>5</issue>):<fpage>1563</fpage>&#x02013;<lpage>71</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5324</pub-id><pub-id pub-id-type="pmid">18316622</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Teillaud</surname><given-names>JL</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response</article-title>. <source>Front Immunol</source> (<year>2011</year>) <volume>2</volume>:<fpage>66</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2011.00066</pub-id><pub-id pub-id-type="pmid">22566855</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Obeid</surname><given-names>M</given-names></name><name><surname>Ortiz</surname><given-names>C</given-names></name><name><surname>Criollo</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy</article-title>. <source>Nat Med</source> (<year>2007</year>) <volume>13</volume>(<issue>9</issue>):<fpage>1050</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nm1622</pub-id><pub-id pub-id-type="pmid">17704786</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group>
<article-title>Immunological aspects of cancer chemotherapy</article-title>. <source>Nat Rev Immunol</source> (<year>2008</year>) <volume>8</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="doi">10.1038/nri2216</pub-id><pub-id pub-id-type="pmid">18097448</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>O&#x02019;Day</surname><given-names>SJ</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Weber</surname><given-names>RW</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><etal/></person-group>
<article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title>. <source>N Engl J Med</source> (<year>2010</year>) <volume>363</volume>(<issue>8</issue>):<fpage>711</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id><pub-id pub-id-type="pmid">20525992</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><etal/></person-group>
<article-title>Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</article-title>. <source>N Engl J Med</source> (<year>2012</year>) <volume>366</volume>(<issue>26</issue>):<fpage>2443</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id><pub-id pub-id-type="pmid">22658127</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Kluger</surname><given-names>H</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Lesokhin</surname><given-names>AM</given-names></name><etal/></person-group>
<article-title>Nivolumab plus ipilimumab in advanced melanoma</article-title>. <source>N Engl J Med</source> (<year>2013</year>) <volume>369</volume>(<issue>2</issue>):<fpage>122</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1302369</pub-id><pub-id pub-id-type="pmid">23724867</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Weinschenk</surname><given-names>T</given-names></name><name><surname>Stenzl</surname><given-names>A</given-names></name><name><surname>Zdrojowy</surname><given-names>R</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival</article-title>. <source>Nat Med</source> (<year>2012</year>) <volume>18</volume>(<issue>8</issue>):<fpage>1254</fpage>&#x02013;<lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nm.2883</pub-id><pub-id pub-id-type="pmid">22842478</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name></person-group>
<article-title>Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines</article-title>. <source>Nat Rev Cancer</source> (<year>2008</year>) <volume>8</volume>(<issue>5</issue>):<fpage>351</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nrc2373</pub-id><pub-id pub-id-type="pmid">18418403</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Doloff</surname><given-names>JC</given-names></name><name><surname>Waxman</surname><given-names>DJ</given-names></name></person-group>
<article-title>Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression</article-title>. <source>Neoplasia</source> (<year>2014</year>) <volume>16</volume>(<issue>1</issue>):<fpage>84</fpage>&#x02013;<lpage>96</lpage><pub-id pub-id-type="doi">10.1593/neo.131910</pub-id><pub-id pub-id-type="pmid">24563621</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Domschke</surname><given-names>C</given-names></name><name><surname>Stoiber</surname><given-names>N</given-names></name><name><surname>Schott</surname><given-names>S</given-names></name><name><surname>Heil</surname><given-names>J</given-names></name><name><surname>Rom</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome</article-title>. <source>Cancer Immunol Immunother</source> (<year>2012</year>) <volume>61</volume>(<issue>3</issue>):<fpage>353</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s00262-011-1106-3</pub-id><pub-id pub-id-type="pmid">21915801</pub-id></mixed-citation></ref></ref-list></back></article>